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ABSTRACT
Sparstolonin B (SsnB) is a novel bioreactive compound isolated from Sparganium
stoloniferum, an herb historically used in Traditional Chinese Medicine as an anti-tumor
agent. SsnB has demonstrated anti-inflammatory properties, inhibiting Toll-like receptor
mediated inflammation in isolated macrophages and in mice. Angiogenesis, the process
of new capillary formation from existing blood vessels, is dysregulated in many
pathological disorders, including atherosclerosis, diabetic retinopathy, and tumor growth.
The goal of the project was to investigate the anti-angiogenic effects of SsnB.
The first part of the project utilized in vitro functional assays to study how SsnB
affected endothelial cells. SsnB inhibited endothelial cell tube formation (Matrigel
method) and cell migration (Transwell method) in a dose-dependent manner. Microarray
experiments with human umbilical vein endothelial cells (HUVECs) and human coronary
artery endothelial cells (HCAECs) demonstrated differential expression of several
hundred genes in response to SsnB exposure (916 and 356 genes, respectively, with fold
change ≥ 2, p < 0.05, unpaired t-test). Microarray data from both cell types showed
significant overlap, including genes associated with cell proliferation and cell cycle.
Flow cytometric cell cycle analysis of HUVECs treated with SsnB showed an increase of
cells in the G1 phase and a decrease of cells in the S phase. Cyclin E2 (CCNE2) and Cell
division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression
through the G1/S checkpoint. Both CCNE2 and CDC6 were downregulated in the
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microarray data. Real Time quantitative PCR confirmed that gene expression of CCNE2
and CDC6 in HUVECs was downregulated after SsnB exposure, to 64% and 35% of
controls, respectively. The data suggest that SsnB may exert its anti-angiogenic
properties by downregulating CCNE2 and CDC6, halting progression through the G1/S
checkpoint.
In the second portion of the project, a chick chorioallantoic membrane (CAM)
assay was utilized to investigate SsnB inhibition of ex vivo angiogenesis. Chick embryos
were exposed to methylcelluose discs containing vehicle control (DMSO) or SsnB.
Chick embryos receiving SsnB discs showed significant reduction in capillary length and
branching relative to the vehicle control group. Overall, SsnB caused a significant
reduction in angiogenesis, demonstrating its ex vivo efficacy.
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CHAPTER 1
INTRODUCTION
Atherosclerosis
Atherosclerosis is a serious chronic disease affecting a significant portion of the
U.S. population and causing many deaths, from conditions such as ischemic stroke and
myocardial infarction. There are many risk factors for atherosclerosis including
hypertension, smoking, diabetes, high-fat diet, and dyslipidemia. Atherosclerosis
specifically involves the formation of plaques within blood vessels, progressing through
several stages (illustrated in Figure 1.1). In the earliest stage, fatty streaks or atheromas
form as lipids and lipoproteins deposit in the tunica intima of the blood vessel. A high
ratio of LDL:HDL favors this event. The lipid deposits become oxidized and induce
injury to the endothelial cells lining the blood vessel. Endothelial injury is a key step in
atherosclerosis; endothelial cells may also be injured by denuding events or by more
subtle hemodynamic changes. Cell adhesion molecules are upregulated in the
endothelium, and inflammatory cells are attracted to the site of injury, including
monocytes which differentiate into macrophages. As macrophages migrate to the area of
oxidized lipids, scavenger receptors and toll-like receptors bind the lipids and help
activate the macrophages to release inflammatory cytokines and mediators. The
macrophages transform into foam cells as they take up oxidized lipids. Additional cells
migrate to the area, including mast cells and leukocytes. An advanced lesion forms as
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smooth muscle cells from the tunica media proliferate, migrate into the plaque, and form
a fibrous cap. The smooth muscle cells may also transform into foam cells. An area of
dead cells and cholesterol crystals forms within the plaque. A capillary network also
grows within the plaque to help provide nutrients, gases, and inflammatory cells to the
growing plaque. Blood vessels within the tunica adventitia, known as the vasa vasorum,
supply this capillary network. As the plaque progresses, the fibrous cap weakens and
ruptures, exposing the highly thrombogenic necrotic core region. Thrombus formation
subsequently ensues. The thrombus may occlude the vessel or become an embolus that
travels to another region of the body (Sluimer and Daemen 2009).

Figure 1.1 Atherosclerotic Plaque Progression.
Plaque formation does not typically occur in wild type mice. However, ApoE
knockout mice and LDL receptor knockout mice show significant plaque progression
after several months on a high fat diet (such as the Western Diet). Plaque formation in
mice can be accelerated by surgical interventions which alter hemodynamics or induce
endothelial injury. These procedures include complete and partial carotid ligation, where
the entire common carotid artery or its branches are ligated with sutures. The resulting
decreased blood flow and oscillatory shear stress reduce the time to plaque formation.
Another model of atherosclerosis in mice is wire-induced endothelial cell injury. In this
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model, a wire is inserted into the carotid artery, and the luminal surface is scraped to
induce endothelial injury. A similar model involves the application of electrical current
to the carotid. Mice may also be injected with lipopolysaccharide, derived from gram
negative bacteria, to induce an inflammatory response and cause atherosclerosis (Nam et
al. 2009).
Intraplaque Angiogenesis
Atherosclerotic plaque rupture is the leading cause of acute cardiovascular events
such as myocardial infarction (“heart attack”) and ischemic stroke. In this process, the
fibrous cap overlying an atherosclerotic plaque fails, resulting in rapid thrombus
formation which may completely occlude the vessel, leading to ischemia and tissue death
downstream of the blockage. Newly developed and recurring myocardial infarction
afflicts approximately 1.1 million people in the USA per year, with a 40% fatality rate;
220,000 of these deaths occur without hospitalization. Roughly 75% of these clinical
events are caused by atherosclerotic plaque rupture. Clearly, methods of stabilizing
atherosclerotic plaques to prevent plaque rupture would have a significant clinical impact
(Sluimer and Daemen 2009).
Research has shown a link between capillary networks within atherosclerotic
plaques and plaque progression and rupture (Sluimer et al. 2009). Under normal
physiological conditions, only thick-walled blood vessels such as the descending aorta
and the common carotid artery contain an intramural capillary network. This network of
blood vessels, known as the vasa vasorum, is situated in the tunica adventitia and outer
third of the tunica media. It supplies the blood vessel wall with nutrients and allows gas
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exchange. Human atherosclerotic arteries have shown extensive intraplaque
angiogenesis, often linked to the vasa vasorum. It has been suggested that hypoxia and/or
reactive oxygen species are responsible for initiating new capillary formation (Khurana et
al. 2005). Capillary networks within atherosclerotic plaques serve as a source of
inflammatory cells, nutrients, and mediators, allowing the neo-intima to expand beyond
the normal wall thickness. Intraplaque angiogenesis is correlated with decreased plaque
stability and increased incidence of plaque rupture, subsequent thrombus formation, and
intra-arterial occlusion. Recent research has suggested that inhibiting angiogenesis may
improve plaque stability and decrease the chances for plaque rupture (Moreno et al. 2004;
Virmani et al. 2005). In addition, inhibiting angiogenesis may decrease plaque formation
by limiting this supply of necessary factors to the plaque region (Sluimer and Daemen
2009).
Oxidative stress and reactive oxygen species (ROS) have been linked to many
different pathological states, including atherosclerosis. ROS are also employed in normal
physiological responses in vascular cells, including intracellular signaling. ROS include
hydrogen peroxide, superoxide anion, nitric oxide (NO), peroxynitrite, and hydroxyl
radical. Sources of ROS include NADPH oxidases, eNOS, lipoxygenases, the
mitochondrial electron chain, and xanthine oxidase. Reactive oxygen species can also be
found in environmental sources, such as cigarette smoke and diesel exhaust fumes.
Certain reactive oxygen species, such as the superoxide anion, may react with NO,
forming peroxynitrite which oxidizes and damages lipid membranes, lipoproteins, and
cellular enzymes. As NO becomes inactivated, vasodilation is impaired, resulting in a
state of hypertension. ROS may also increase cell adhesion molecules in endothelial
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cells, leading to a state of vascular inflammation. All of the preceding effects predispose
the vasculature to atherosclerosis (Ushio-Fukai et al. 1999).
Steps Involved in Angiogenesis
Angiogenesis is one mechanism of new blood vessel formation. Specifically,
angiogenesis refers to capillary formation from existing blood vessels; whereas,
vasculogenesis refers to the de novo formation of blood vessels during embryogenesis.
Angiogenesis plays an important role in many normal events in the body, including
wound healing, embryogenesis, and female reproductive processes. During these normal
processes, angiogenesis is highly regulated. Unregulated angiogenesis contributes to
many pathological conditions, such as rheumatoid arthritis, psoriasis, retinopathy, and
tumor growth and metastasis. Clearly, angiogenesis is an important event in the human
body. In addition, endothelial cells play a key role during angiogenesis. Therefore, an
understanding of endothelial cell functions is essential when discussing angiogenesis
(Bussolino, Mantovani, and Persico 1997).
Angiogenesis is a complex event that occurs in several stages and involves
interactions between cells, soluble factors, and extracellular matrix molecules. First,
proteolytic enzymes break down the basement membrane of an existing blood vessel.
Endothelial cells with the help of proteolytic enzymes, including matrix
metalloproteinases (MMPs) and the plasminogen activator system (PA), break down the
basement membrane and invade the surrounding tissues. The PA system is comprised of
the serine proteases urokinase-type plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA) that convert plasminogen into its active form, plasmin.
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Plasmin degrades numerous extracellular matrix proteins, including fibronectin, laminin,
and fibrin. Plasmin also helps activate many MMPs. Matrix metalloproteinases are more
specific in the matrix molecules that they degrade. After the basement membrane of the
blood vessel is broken down, endothelial cells migrate into the surrounding tissue and
proliferate. Growth factors and other soluble proteins in the ECM often facilitate and
regulate this process. The growth factors that are stored bound to the ECM can be
released as the ECM is degraded by proteases. Certain growth factors, such as vascular
endothelial growth factor, act as chemoattractants that facilitate the migration of
endothelial cells to certain locations. After proliferation and migration, the endothelial
cells form a new lumen and start to secrete extracellular matrix molecules, ultimately
forming a new capillary (Liekens, De Clercq, and Neyts 2001).
Preliminary Research
The strong connection between plaque instability and angiogenesis initially
captured our attention. What causes intraplaque angiogenesis? How can we inhibit
intraplaque angiogenesis? Will inhibiting angiogenesis prevent plaque rupture? These
were questions that first intrigued us. Our preliminary research sought to investigate the
cause and process of angiogenesis within atherosclerotic plaques. We hypothesized that
reactive oxygen species were responsible for capillary formation within plaques. Later
we decided to investigate the anti-angiogenic properties of the plant derived compound
Sparstolonin B. We will first begin with a brief description of the preliminary research
conducted on reactive oxygen species and intraplaque angiogenesis. The majority of this
dissertation will then be devoted to examining Sparstolonin B and its anti-angiogenic
properties.
6

To study the relationship between reactive oxygen species, angiogenesis, and
atherosclerosis, a mouse model of atherosclerosis was utilized. In this model, ApoE
knockout mice underwent left carotid ligation. The ligated mice were placed on a high
cholesterol diet (Paigen Diet - 1.25% cholesterol) for 0, 7, 14, and 21 days. During this
time, atherosclerotic plaques developed within each ligated carotid artery. After the
appropriate time course, the mice were sacrificed and perfused with heparinized saline
and neutral buffered formalin. Both left and right carotid arteries were dissected in an
entire block, including the trachea and esophagus. Carotid blocks were fixed, processed,
and embedded in paraffin. The specimens were sectioned into 5 um sections and
collected on glass slides. Plaque formation was demonstrated by hematoxylin and eosin
(H&E) and Masson’s Trichrome staining. To investigate reactive oxygen species
formation in the plaque, antibodies against 8-isoprostane (8-IP) were chosen. 8-IP forms
after reactive oxygen species react with components of the cell membrane. The slides
were deparaffinized and hydrated; immunohistochemical staining was performed to
detect 8-IP. A colorimetric reaction was utilized to detect the presence of 8-IP. Light
microscopic images were acquired with a 10X objective lens, and the stained area within
sections was measured with Image-Pro Plus image analysis software.
Immunohistochemical staining for 8-IP was performed on carotid artery sections
taken from mice that had undergone a complete carotid artery ligation for 0, 7, 14, or 21
days. The staining results were analyzed by dividing each carotid image into three
separate regions (intima, media, and adventitia) and measuring the positively stained area
in each region (see Appendix, Figure A.1). The media region exhibited the least amount
of staining in all sections; whereas, the adventitia exhibited the most staining. Day 14
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specimens demonstrated the largest stained area, and Day 0 showed the least staining.
Overall, 8-IP seemed to increase over time and peak on Day 14. Afterwards, 8-IP
staining dropped on Day 21. In addition, Day 14 and 21 sections showed areas of 8-IP
staining that overlapped with capillary networks identified by antibody Ter 119
(erythroid cell marker) and hematoxylin and eosin stains. Day 7, 14, and 21 sections
exhibited 8-IP staining in areas containing foam cells and adventitial fat cells. Day 0
staining was confined to the endothelium. These results suggest that ROS formation
increases during atherosclerotic plaque development in this mouse model.
The results demonstrated a potential role for reactive oxygen species in capillary
formation within atherosclerotic plaques. 8-isoprostane is formed when reactive oxygen
species react with arachidonic acid, a component of cellular membranes. Since 8-IP is
elevated in the neointima at 14 and 21 days after carotid ligation, this implies that
reactive oxygen species are present in the atherosclerotic plaques. The colocalization of
8-IP and intraplaque capillary networks suggests that ROS may be involved in
neovascularization. Day 14 sections demonstrate 8-IP staining before intraplaque vessels
are present, supporting this hypothesis. Hypoxia has been show to be a major driving
force for angiogenesis, but other factors, such as reactive oxygen species, may play a key
role in this process. ROS may activate many of the same angiogenic pathways as
hypoxia, including the stabilization of the transcription factor hypoxia inducible factor
(HIF)-1α which upregulates VEGF. Future directions could incorporate research into the
mechanisms of ROS stimulation of angiogenesis and additional markers of ROS, such as
4-hydroxynonenal (4-HNE).
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Angiogenesis Inhibition and Sparstolonin B
The research outlined above explored a potential stimulus for intraplaque
angiogenesis. After completing this research, it was deemed important to investigate new
ways to inhibit angiogenesis. New methods to inhibit angiogenesis may hold the key to
new treatments not only for atherosclerosis, but also for various other angiogenesisrelated pathological conditions, including psoriasis, cancer, and rheumatoid arthritis.
Sparstolonin B (SsnB) is a newly isolated compound from the aquatic herb, Sparganium
stoloniferum. Based on prior research conducted on both SsnB and the parent plant
(described in the following pages), we hypothesized that SsnB would inhibit
angiogenesis.
Angiogenesis may be inhibited at multiple steps. Growth factors, including
Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF),
are suitable targets. Current approaches to sequester VEGF include soluble VEGF
receptors and neutralizing antibodies against VEGF. Intracellular signaling molecules,
including tyrosine kinases, can be inhibited to prevent receptor-mediated activation of
endothelial cells. There also exist natural angiogenesis inhibitors, including endostatin,
retinoids, and fibronectin fragment, which may be targeted for angiogenesis inhibition.
Angiogenesis inhibitors often target endothelial cells through the inhibition of cell
proliferation, migration, and protease production. Current research into angiogenesis
inhibition has demonstrated ways to limit atherosclerosis. By inhibiting intraplaque
angiogenesis, necessary factors, such as inflammatory cells, oxygen, and mediators, are
not delivered to the growing plaque, diminishing plaque growth. Plaque stability may
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also be improved, decreasing the likelihood of plaque rupture and subsequent thrombosis
and stroke or myocardial infarction (Pandya, Dhalla, and Santani 2006).
Sparstolonin B (SsnB) is a novel bioactive compound isolated from the plant
Sparganium stoloniferum by Dr. Qiaoli Liang from the laboratory of Dr. Daping Fan at
the University of South Carolina School of Medicine (Liang et al. 2011). Sparganium
stoloniferum is a perennial, aquatic plant grown in North and East China, whose tubers
have long been used in Traditional Chinese Medicine (TCM) for the treatment of several
inflammatory diseases and as an anti-spasmodic and anti-tumor agent. Previous work
with this herb has mainly dealt with its extracts. SsnB is one of several chemical
compounds that have been isolated and characterized from Sparganium stoloniferum.
NMR and X-ray crystallography have identified SsnB as a polyphenol with structural
similarities to isocoumarins and xanthone (see Figure 1.2). Isocoumarins are a class of
compounds that often exhibit anti-coagulant, anti-inflammatory, and anti-tumor
properties (Qiu 2008; Liang et al. 2011; Xiong et al. 2009).
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Figure 1.2 Structure of SsnB
SsnB shows potential as a safe, non-toxic pharmaceutical agent for the treatment
of several pathological conditions. At concentrations up to 100 µM, SsnB does not
exhibit cytotoxic effects on various cell types, including peritoneal mouse macrophages,
phorbol myristate acetate (PMA)-differentiated THP-1 macrophages, Human Umbilical
Vein Endothelial Cells (HUVECs), Human Aortic Smooth Muscle Cells (HASMCs), and
monocytic THP-1 cells. Prior research has shown that SsnB exhibits strong antiinflammatory effects on mouse and human macrophages, selectively inhibiting the
inflammatory responses of macrophages to ligands for Toll-like Receptors 2 and 4 (TLR2
and TLR4). SsnB has also been shown to suppress downstream signaling pathways after
TLR2 and TLR4 activation, including MAPK and NF-κB. These findings suggest that
SsnB may be an antagonist to TLR2 and TLR4 (Liang et al. 2011).
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Targeting endothelial cell proliferation has shown potential in the area of
angiogenesis inhibition. Endothelial cell proliferation may be inhibited in numerous
ways, including the downregulation of cell cycle regulatory proteins (Pandya, Dhalla, and
Santani 2006). Cyclins and cyclin dependent kinases are regulatory proteins that control
progression through the cell cycle by regulating specific cell cycle checkpoints. Cyclins
help activate cyclin dependent kinases, which phosphorylate downstream proteins that
allow cells to progress through these checkpoints. Cyclin E2 (CCNE2) and Cell Division
Cycle 6 (CDC6) are regulatory proteins that control progression through the G1
checkpoint (see Figure 1.3). Downregulation of CCNE2 and CDC6 could trap cells at the
G1 checkpoint and prevent endothelial cells from entering the final stages of cell division
(Wu et al. 2009; Borlado and Mendez 2008). We have hypothesized that SsnB may exert
anti-angiogenic effects by downregulating CCNE2 and CDC6, trapping endothelial cells
at the G1 checkpoint and preventing complete cell division.

Figure 1.3 Cell Cycle
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The parent plant Sparganium stoloniferum has been used for centuries in
Traditional Chinese Medicine for the treatment of cancer. Furthermore, previously
published research has shown that extracts and other isolated chemical compounds from
this herb, including a sucrose ester, a phenylpropanoid glycerol, carboxylic acid esters,
and a phenylpropanoid glycoside, have demonstrated potent anti-cancer effects (Li et al.).
Compounds used to treat tumors often possess the ability to inhibit angiogenesis, among
other properties. This enables these compounds to limit blood vessel growth into
growing tumors, limiting the supply of necessary nutrients and cells and subsequently
inhibiting tumor growth (Meng et al.). Since SsnB is derived from this plant used in
cancer treatment, we tested the hypothesis that SsnB may possess anti-angiogenic
properties in addition to its already established anti-inflammatory properties. Moreover,
SsnB offers advantages over current protein angiogenesis inhibitors, including angiostatin
and thrombospondin, which require parenteral administration.
Specific Aims
The overall goal of the project is to demonstrate that SsnB inhibits angiogenesis
and to determine its mechanism of action in blocking angiogenesis. Our initial in vitro
studies demonstrated the potential of SsnB as an anti-angiogenic agent, which inhibits
human endothelial cell tube formation and migration. Our microarray data showed how
SsnB affected gene expression, with an enrichment of differentially regulated genes
associated with cell proliferation, replication, migration, and cell cycle. SsnB arrested
endothelial cell division in the G1 phase in association with downregulating the cell cycle
proteins cdc6 and cyclin E2. Furthermore, we demonstrated that SsnB inhibited ex vivo
angiogenesis in the chick chorioallantoic membrane assay. Overall, we hypothesize that
13

SsnB inhibits angiogenesis by targeting endothelial cell cycle progression, cell migration,
and chemotaxis. The project may ultimately demonstrate the potential of SsnB as a
pharmaceutical compound used to inhibit angiogenesis and possibly to stabilize
atherosclerotic plaques.
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Specific Aim 1 – Functional Assays:
To demonstrate the anti-angiogenic effects of SsnB through in vitro functional assays
using human endothelial cells.
Specific Aim 2 – Mechanistic Studies:
A.

Microarray:
To test the effects of SsnB on the gene expression profile of Human Umbilical
Vein Endothelial Cells (HUVECs) and Human Coronary Artery Endothelial Cells
(HCAECs).

B.

Cell Cycle Regulation:
To investigate how SsnB affects expression of genes for cell cycle regulatory
proteins and progression through the cell cycle.

Specific Aim 3 – Ex vivo Studies:
To demonstrate the anti-angiogenic effects of SsnB in the ex vivo chick chorioallantoic
membrane (CAM) assay.
Specific Aim 1 involved the use of several in vitro functional assays to reveal if
and how SsnB inhibited angiogenesis-related functions in isolated endothelial cells.
Specific Aim 2 further investigated the mechanism of inhibition by examining changes in
gene expression with microarrays and determining how SsnB affected cell cycle
progression. Specific Aim 3 demonstrated angiogenesis inhibition in an ex vivo system.
Overall, SsnB exhibits many diverse effects, including anti-inflammatory, anti-
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angiogenic, and cytostatic properties, which suggest that it may have potential therapeutic
uses for a plethora of disorders.
.
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CHAPTER 2
SPARSTOLONIN B INHIBITS PRO-ANGIOGENIC FUNCTIONS AND BLOCKS CELL CYCLE
PROGRESSION IN ENDOTHELIAL CELLS

Abstract
Sparstolonin B (SsnB) is a novel bioactive compound isolated from Sparganium
stoloniferum, an herb historically used in Traditional Chinese Medicine as an anti-tumor
agent. Angiogenesis, the process of new capillary formation from existing blood vessels,
is dysregulated in many pathological disorders, including diabetic retinopathy, tumor
growth, and atherosclerosis. In functional assays, SsnB inhibited endothelial cell tube
formation (Matrigel method) and cell migration (Transwell method) in a dose-dependent
manner. Microarray experiments with human umbilical vein endothelial cells (HUVECs)
and human coronary artery endothelial cells (HCAECs) demonstrated differential
expression of several hundred genes in response to SsnB exposure (916 and 356 genes,
respectively, with fold change ≥ 2, p < 0.05, unpaired t-test). Microarray data from both
cell types showed significant overlap, including genes associated with cell proliferation
and cell cycle. Flow cytometric cell cycle analysis of HUVECs treated with SsnB
showed an increase of cells in the G1 phase and a decrease of cells in the S phase. Cyclin
E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control cell
cycle progression through the G1/S checkpoint. Both CCNE2 and CDC6 were
downregulated in the microarray data. Real Time quantitative PCR confirmed that gene
expression of CCNE2 and CDC6 in HUVECs was downregulated after SsnB exposure, to
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64% and 35% of controls, respectively. The data suggest that SsnB may exert its antiangiogenic properties in part by downregulating CCNE2 and CDC6, halting progression
through the G1/S checkpoint.
Introduction
Sparstolonin B (SsnB) is a novel bioactive compound isolated from the plant
Sparganium stoloniferum, a perennial, aquatic plant grown in North and East China,
whose tubers have long been used in Traditional Chinese Medicine (TCM) for the
treatment of several inflammatory diseases and as an anti-spasmodic and anti-tumor
agent. NMR and X-ray crystallography have identified SsnB as a polyphenol with
structural similarities to isocoumarins, a class of compounds that often exhibit anticoagulant, anti-inflammatory, and anti-tumor properties (Qiu 2008; Xiong et al. 2009;
Liang et al. 2011). SsnB may hold potential as a safe, non-toxic pharmaceutical agent for
the treatment of several pathological conditions. At concentrations up to 100 µM, SsnB
does not exhibit cytotoxic effects on various cell types, including mouse peritoneal
macrophages, HUVECs, human aortic smooth muscle cells, and monocytic THP-1 cells.
Prior research has shown that SsnB exhibits strong anti-inflammatory effects on mouse
and human macrophages by selectively inhibiting the inflammatory responses of
macrophages to ligands for Toll-like Receptor (TLR) 2 and TLR4. SsnB has also been
shown to suppress downstream signaling pathways after TLR2 and TLR4 activation,
including MAPK and NF-κB (Liang et al. 2011). These findings suggest that SsnB may
be an antagonist to TLR2 and TLR4.
Angiogenesis refers to capillary formation from existing blood vessels.
Angiogenesis plays an important role in many physiological events in the body, including
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wound healing, embryogenesis, and female reproductive processes (Folkman 1971; Risau
1997). During these normal processes, angiogenesis is highly regulated. Unregulated,
excessive angiogenesis contributes to many pathologies, such as rheumatoid arthritis,
psoriasis, retinopathy, and tumor growth and metastasis (Staton, Reed, and Brown 2009).
Inhibiting pathological angiogenesis may prove to be an effective therapy for these
angiogenesis-related diseases.
Angiogenesis is a complex process that occurs in several stages and involves
interactions between cells, soluble factors, and extracellular matrix molecules.
Endothelial cells play a key role in angiogenesis. Endothelial cells can secrete proteolytic
enzymes which break down the basement membrane of an existing blood vessel,
allowing the cells to invade the surrounding tissues, migrate in response to an angiogenic
stimulus, and proliferate. Growth factors and other soluble proteins in the ECM often
facilitate and regulate this process, including vascular endothelial growth factor (VEGF).
The endothelial cells form a new lumen, start to secrete extracellular matrix molecules,
and ultimately form a new capillary (Bussolino, Mantovani, and Persico 1997; Carmeliet
2003; Liekens, De Clercq, and Neyts 2001). Mural cells are also recruited to the site and
play an important role in angiogenesis. Angiogenesis may be inhibited at any of these
key steps (Pandya, Dhalla, and Santani 2006). Targeting endothelial cell proliferation,
cell migration, and chemotaxis have shown potential in angiogenesis inhibition.
In the present study, we demonstrate that SsnB inhibits endothelial cell functions
related to angiogenesis in several in vitro functional assays. The data suggests the
potential of SsnB as an anti-angiogenic agent by showing inhibition of human endothelial
cell tube formation and migration. We have also examined the effects of SsnB on
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endothelial cell gene expression, focusing in particular on pathways related to
angiogenesis. In addition, our data show that SsnB arrests endothelial cell division in the
G1 phase and downregulates the cell cycle proteins cdc6 and cyclin E2. Overall, these
findings add anti-angiogenic and cytostatic properties to the list of diverse effects
exhibited by SsnB.
Experimental Procedures
Materials – Sparstolonin B was purified from the plant Sparganium stoloniferum
according to previously published methods (Liang et al. 2011). The purity of SsnB was
determined to be greater than 99% by HPLC, and a stability test was utilized to ensure
that samples were consistently > 99% pure.
Cell Culture - Human coronary artery endothelial cells (HCAECs), human umbilical vein
endothelial cells (HUVECs), and human cardiac microvascular endothelial cells
(HMVECs) were obtained from Lonza (Hopkinton, MA) and cultured on polystyrene,
tissue culture-treated petri plates (100 X 20 mm) coated with 0.1% gelatin. HUVECs,
HCAECs, and HMVECs were cultured in endothelial cell medium supplemented with
10% fetal bovine serum (FBS) and endothelial cell mitogen / growth supplement
(Biomedical Technologies, Stoughton, MA). The endothelial cell medium was replaced
every 2-3 days, and the cells were passaged after complete confluence was reached.
Confluent plates were trypsinized and split, and the cells were cultured until the fourth
passage was reached.
Matrigel Tube Formation Assay - To initially determine if SsnB inhibited proangiogenic cell functions, a tube formation assay with Matrigel was performed. Growth
factor reduced Matrigel (BD Biosciences, Bedford, MA) was added to the wells of a 96
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well polystyrene culture plate and incubated at 37 °C for 30 minutes. Cells (HUVECs,
HCAECs, or HMVECs at passage 2 to 4) were added to each well to reach a final number
of 20,000 cells per well. SsnB was added to the wells at a concentration of 1, 10, or 100
µM. Endothelial cell medium with DMSO (0.1%) was used as a vehicle control. Each
group contained 4 replicates. The plates were placed in an incubator for 4 h. During the
incubation, the endothelial cells formed elongated structures called cords, also known as
tubes. After 4 h, neutral buffered formalin was added to fix the cells. Pictures of three
non-overlapping fields were taken from each well. The lengths of single cell endothelial
cords were measured with Image-Pro Plus (Media Cybernetics, Silver Spring, MD), and
the sum of tube lengths for each well was determined. The average total length and
standard deviation for each group were determined, and the appropriate statistical tests
(ANOVA and Newman-Keuls) were completed. The tube formation assay was replicated
three times for both HUVECs and HCAECs. The assay was also repeated with cardiac
HMVECs.
Cell Viability - A Live/Dead assay (Invitrogen, Eugene, OR) was utilized to
investigate the effect of SsnB on cell viability. The Matrigel tube formation experiment
was repeated with HUVECs in chamber slides at a concentration of 20,000 cells per well.
The cells were treated with SsnB (1, 10, or 100 µM) or Vehicle Control (0.1% DMSO) as
described above. After four hours of incubation, the slides were removed. A chamber
slide containing HUVECs treated with 70% methanol for 30 minutes was used as a
control for dead cell staining. The slides were aspirated and washed with PBS, and
EthD-1 and calcein AM were added to each well. The plates were incubated in the dark,
and images were taken with a light microscope at 10X magnification..
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Transwell Insert Cell Migration Assay - The cell invasion assay was performed
with a Transwell insert system (6.5 mm diameter inserts with 8.0 µm pores in a
polycarbonate membrane situated in wells of 24 well polystrene, tissue culture treated
plates, Corning Incorporated, Corning, NY ). The Transwell inserts were coated with
0.1% gelatin for 30 min and incubated in low serum medium for 1 h. Cultured HUVECs
were trypsinized and then resuspended in low serum medium (0.5% fetal bovine serum
without endothelial cell mitogen), and added at 50,000 cells per insert. The cells were
allowed to adhere to the inserts for 30 min. Next, various concentrations of SsnB
(0.0001, 0.001, 0.01, 0.1, 1, 10, and 100 µM) or vehicle control (0.1% DMSO) were
added to the Transwell inserts. After 30 min, the medium in the lower chamber for the
experimental groups was replaced with low serum medium containing 10 ng/ml VEGF,
establishing a chemoattractant gradient between the top insert and lower chamber. For
the negative control group, the medium was replaced with low serum medium (0.5% fetal
bovine serum). The plates were incubated for 8 h at 37°C. During the incubation, the
cells migrated through the pores of the Transwell insert towards the lower chamber. At
the end of this period, cells on the upper surface of the insert were removed, and migrated
cells on the bottom side were fixed in formalin and stained with Hoechst dye (a
fluorescent nuclear stain). The filter inserts were removed from the wells and mounted
on glass slides. Cells were counted from four random fields observed with a 10X
objective lens. The cell migration experiments were repeated three times at high SsnB
concentrations (0.1, 1, 10, 100 µM) and one time at low SsnB concentrations (0.0001,
0.001, 0.01, 0.1 µM) for HUVECs.
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Cell Cycle Analysis - Cell cycle analysis was performed using propidium iodide
staining and flow cytometry. HUVECs (approximately 75% confluent) cultured in 6 well
polystyrene culture plates coated with 0.1% gelatin were serum starved for 24 hours in
low serum medium containing 0.5% fetal bovine serum and no endothelial cell mitogen
to synchronize the cells in the G0/G1 phase. After 24 hours, the low serum medium was
replaced with treatments of either 100 µM SsnB or vehicle control (0.1% DMSO) diluted
in complete growth medium (10% fetal bovine serum with endothelial cell mitogen) in
triplicate. The treated cells were incubated for 24, 30, and 36 hours. After incubation,
the cells were trypsinized, transferred to 5 ml polysytrene round bottom tubes (12 X 75
mm), and centrifuged. The medium was aspirated, and the cells were washed with PBS.
After fixing the cells with ice-cold 70% ethanol for 15 min, the cells were centrifuged
and stained with propidium iodide for 30 min. The samples were then analyzed with a
flow cytometer (Beckman Coulter FC500). The unstained and stained cell groups were
used to calibrate the settings on the flow cytometer. The data were collected and
analyzed with ModFit software.
Microarray Analysis - Confluent plates (100 X 20 mm polystyrene, tissue culturetreated petri plates coated with 0.1% gelatin, 75% confluent) of HUVECs and HCAECs
(four plates for HUVECs, n=2, and six plates for HCAECs, n=3) were chosen for the
microarray experiments. Half of the plates received complete growth medium (10% fetal
bovine serum with endothelial mitogen) containing vehicle control (0.1% DMSO), and
the remaining plates received complete growth medium containing 100 µM SsnB. The
plates were incubated for 24 h to allow SsnB to have an effect on cellular gene
expression. Following incubation, RNA isolation was completed with the RNeasy Mini
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kit from Qiagen. The cells were lysed, and RNA was isolated by using the RNeasy spin
columns and following the protocol provided by Qiagen. Purified RNA was sent to the
Medical University of South Carolina Proteogenomics Facility for microarray analysis.
The GeneChip Human Genome U133 Plus 2.0 Array was utilized to track changes in
gene expression due to SsnB treatment. Complete data was uploaded to the NCBI Gene
Expression Omnibus database (accession number GSE44598).
Real Time RT-PCR - After a careful analysis of the microarray data, key genes
(CDC6, CCNE2, KITLG, ALDH3A1, CCNB1, CDC2, HMMR, DIAPH3, ANLN, and
CDKN3) were chosen for quantitative real-time PCR (qRT-PCR) to verify the gene
expression results. HCAECs and HUVECs were exposed to SsnB or vehicle control for
24 h (as previously described in the microarray section). For RT-PCR, RNA was isolated
from the cells with the RNeasy Mini kit as described previously. After forward and
reverse primer kits (Qiagen, Valencia, CA) were selected, the RNA was amplified. The
one-step RT-PCR reactions were completed on the BioRad iCycler thermal cycler system
in the Instrumentation Resource Facility at the USC School of Medicine. The expression
levels were normalized, and RNA levels were quantified.
Data Analysis - Microarray data analysis, including data normalization (robust
multi-array average), identification of differentially expressed genes (comparative
analyses with dChip software), and heat map construction, was carried out to determine
how SsnB affects gene expression and affected pathways (n = 2 for HUVECs and n = 3
for HCAECs). After a careful analysis of the microarray data, several key genes were
chosen for qRT-PCR to verify the gene expression results. The genes were chosen based
on the following criteria: fold change ≥ 2, p < 0.05, unpaired t-test with a false discovery
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rate approximating 0%, appearing in both data sets (HUVECs and HCAECs), and gene
function relating to cell proliferation and/or angiogenesis. For qRT-PCR, the expression
levels were normalized to the housekeeping gene GAPDH, and RNA levels were
compared between groups with the ∆∆Ct method.
Results
SsnB inhibits endothelial cell tube formation and cell migration - Figures 2.1 and
2.2 show representative results from the tube formation and cell migration assays with
HUVECs. SsnB treatment resulted in a dose-dependent inhibition of HUVEC tube
formation at concentrations between 1 and 100 µM (p < 0.05, Newman-Keuls test). SsnB
also demonstrated a dose-dependent inhibition of VEGF-induced cell migration at
concentrations between 0.0001 and 0.1 µM (p < 0.05), which leveled off between 0.1 and
100 µM (p < 0.05). Experiments with HCAECs also demonstrated a dose-dependent
inhibition (between 1 and 100 µM) of endothelial cell tube formation on the substrate
Matrigel (Figure 2.1). A dose-dependent inhibition of tube formation was also seen with
cardiac HMVECs (see Appendix, Figure A.2). Results from the live/dead assay with
HUVECs showed that SsnB had no effect on cell viability at the concentrations used.
Cells treated with SsnB or vehicle control showed positive staining for live cells, but no
staining for dead cells (red fluorescence). These data suggest that SsnB is able to inhibit
endothelial cell morphogenesis and that cell migration, a crucial process in angiogenesis,
may play a role.
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Figure 2.1 SsnB inhibits endothelial cell tube formation on Matrigel. A. Total tube
length as a function of SsnB concentration in HUVECs. B. Total tube length as a function
of SsnB concentration in HC
HCAECs. *p < 0.05 vs. vehicle control, Newman-Keuls
Keuls test. C.
Representative micrographs demonstrating tube formation in HUVECs (left – vehicle
control, right – 100 µM SsnB).
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Figure 2.2 SsnB inhibits endothelial cell migration. A. Migrated cells as a function
fu
of
SsnB concentration (0.1 to 100 µM). B. Migrated cells as a function of SsnB
concentration (0.0001 to 0.1 µM) shows a dose
dose-dependent
dependent response. *p < 0.05 vs. vehicle
control, Newman-Keuls
Keuls test. C. Representative micrographs demonstrating cell migration
migra
(left – vehicle control, center – negative control, right – 100 µM SsnB).
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SsnB arrests endothelial cells in the G1 phase of the cell cycle - Figure 2.3 depicts
representative results from the cell cycle experiments. In comparison to vehicle controls,
flow cytometric cell cycle analysis of HUVECs treated with SsnB showed an increase of
cells in the G1 phase and a decrease of cells in the S phase after 24, 30, and 36 hours of
treatment. In untreated cells, the percentage of cells in S phase decreased and the
percentage in G2/M increased from 24 to 36 hours after addition of growth medium, as
expected once cells begin to re-enter and move through the cell cycle. Overall, these
results imply that endothelial cells are being arrested in the G0/G1 phase, suggesting an
inhibition of cell proliferation, an important step in angiogenesis.
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Figure 2.3 SsnB arrests endothelial cells in the G1 phase of the cell cycle. A. After 24,
30, and 36 hours of treatment, 100 µM SsnB decreased the percentage of cells in the S
phase and increased the percentage of cells in the G1 phase. *p < 0.005 vs. corresponding
vehicle control, Newman-Keuls test. B. Representative cell cycle data demonstrating the
increase in G1 cell percentage and decrease in S phase cell percentage after 24 hours of
SsnB treatment (left - vehicle control, right - SsnB)
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SsnB changes the expression of genes associated with cell cycle and cell
proliferation - Microarray experiments demonstrated differential expression of several
hundred genes in response to SsnB exposure (916 genes for HUVECs and 356 genes for
HCAECs, fold change ≥ 2, p < 0.05, unpaired t-test with a false discovery rate
approximating 0%). Supplementary Table A.1 and Supplementary Table A.2 present the
results of the gene function enrichment analysis for HUVECs and HCAECs, respectively.
Overall, microarray data from both cell types showed significant overlap, including genes
in pathways associated with cell proliferation, cytoskeleton, chemotaxis, and cell cycle,
all areas implicated in angiogenesis. These results are consistent with the data obtained
from the cell migration and cell cycle functional studies.

From this microarray study, it

is clear that SsnB regulates genes involved in angiogenic processes in HUVECs and
HCAECs.
Real Time RT-PCR - Following microarray data analysis, key genes (listed in
Table 2.1) were chosen for verification with real time RT-PCR. Cyclin E2 (CCNE2) and
Cell division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression
through the G1/S checkpoint. Both CCNE2 and CDC6 were downregulated in the
microarray data. qRT- PCR confirmed that gene expression of CCNE2 and CDC6 was
downregulated after SsnB exposure to 64% and 35% of controls respectively for
HUVECs and to 57% and 14% of controls respectively for HCAECs. Kit-Ligand
(KITLG), also known as stem cell factor, is a protein involved in the differentiation and
growth of stem cells. Aldehyde dehydrogenase 3 family, member A1 (ALDH3A1) is a
protein involved in the aryl hydrocarbon receptor pathway. These genes were chosen for
further study because they were highly upregulated by SsnB treatment in the microarray
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data set. In HUVECs, qRT-PCR analysis demonstrated that KITLG and ALDH3A1
expression was upregulated to 400% and 1280% of controls, respectively. In HCAECs,
KITLG and ALDH3A1 expression was upregulated to 260% and 4620% of controls,
respectively. The microarray data was supported in both data sets.
Table 2.1 Comparison of RT-PCR and Microarray Results. Fold expression change vs.
vehicle control.
HUVECs
Gene

KITLG
ALDH3A1
HMMR
DIAPH3
ANLN
CDKN3
CCNB1
CDC2
CDC6
CCNE2

PCR
2∆∆Ct
value

Fold change
value

4.0
12.8
0.24
0.19
0.20
0.18
0.40
0.14
0.35
0.64

6.2
7.7
0.11
0.34
0.09
0.19
0.19
0.08
0.23
0.24

HCAECs

Microarray
p-value

PCR
2∆∆Ct
value

Microarray
Fold change
value

p-value

0.02795
0.00609
0.03073
0.03248
0.00900
0.01471
0.02304
0.00440
0.01527
0.01814

2.6
46.2
0.062
0.26
0.13
0.22
0.13
0.17
0.14
0.57

2.1
8.8
0.20
0.38
0.11
0.18
0.16
0.20
0.18
0.38

0.00010
0.00001
0.00006
0.00019
0.000001
0.00018
0.00003
0.00004
0.00185
0.00180

Discussion
Pathological angiogenesis is associated with many disorders, including
rheumatoid arthritis, diabetic retinopathy, and psoriasis. Recent research has shown that
inhibiting angiogenesis may prove to be an effective therapeutic option in treating these
disorders. In the present study, potential anti-angiogenic effects of SsnB were
demonstrated in several in vitro functional assays with endothelial cells, including the
Matrigel tube formation assay and the Transwell insert cell migration assay. SsnB was
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also shown to arrest endothelial cells in the G1 phase of the cell cycle. The cellular
functions tested in these assays represent key steps in angiogenesis that are inhibited by
SsnB, including cell proliferation, cell migration, and chemotaxis. To further investigate
the mechanism of action for SsnB, we utilized microarray analysis to examine how SsnB
affected gene expression in endothelial cells. After SsnB exposure, genes associated with
cell proliferation, cell cycle, chemotaxis, and the cytoskeleton were differentially
regulated in both HUVECs and HCAECs. Our data suggest that SsnB alters gene
expression in these pro-angiogenic pathways.
Targeting endothelial cell proliferation has shown potential in the area of
angiogenesis inhibition. Endothelial cell proliferation may be inhibited in numerous
ways, including the downregulation of cell cycle regulatory proteins (Pandya, Dhalla, and
Santani 2006). Cyclins and cyclin dependent kinases are regulatory proteins that control
progression through the cell cycle by regulating specific cell cycle checkpoints. Cyclins
help activate cyclin dependent kinases, which phosphorylate downstream proteins that
allow cells to progress through these checkpoints. Cyclin E2 (CCNE2) and Cell division
cycle 6 (CDC6) are regulatory proteins that control progression through the G1/S
checkpoint. CDC6 regulates DNA replication, and cyclin E2 activates cyclin-dependent
kinase 2 (Wu et al. 2009; Borlado and Mendez 2008). Downregulation of CCNE2 and
CDC6 will trap cells at the G1/S checkpoint and prevent endothelial cells from initiating
DNA replication. The cell cycle regulatory proteins, Cyclin E2 (CCNE2) and Cell
division cycle 6 (CDC6), were both downregulated by SsnB treatment. Overall, our data
suggest that SsnB downregulates the cell cycle regulatory proteins CCNE2 and CDC6,
potentially trapping cells in the G1 phase and hindering cell proliferation, an important
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step in angiogenesis (Nigg 2001; Sullivan and Morgan 2007; Tassan et al. 1994; O'Farrell
2001).
Our data shows that SsnB affects the gene expression of additional cell cycle
regulatory proteins, including cyclin B1 (CCNB1) and cyclin dependent kinase 1
(CDC2). CCNB1 and CDC2 are regulatory proteins that control progression through the
G2/M checkpoint. Downregulation of CCNB1 and CDC2 will trap cells at the G2/M
checkpoint and prevent endothelial cells from entering the final stages of cell division.
Table 2.1 demonstrates that CCNB1 and CDC2 were both downregulated by SsnB. In
addition to preventing cell progression through the G1/S checkpoint, SsnB may also
prevent progression through the G2/M checkpoint by downregulating these additional
cell cycle proteins (Nigg 2001; Sullivan and Morgan 2007; Tassan et al. 1994; O'Farrell
2001). This effect is less readily seen due to blockage at the G1/S checkpoint.
Sparganium stoloniferum has long been used in Traditional Chinese Medicine for
the treatment of cancer and seizures. Major chemical components from the stem and
rhizome, including flavonoids, saponins, and phenylpropanoids, are responsible for these
therapeutic effects (Li et al.). Anti-tumor agents often exhibit anti-angiogenic effects,
among other cancer suppressing properties. Inhibiting angiogenesis cuts tumors off from
the vasculature, limiting growth and metastasis (Meng et al.). Previously published
research has shown that extracts derived from Sparganium stoloniferum have
demonstrated potent anti-cancer effects. Isolated chemical compounds from this herb,
including a sucrose ester, a phenylpropanoid glycerol, carboxylic acid esters, and a
phenylpropanoid glycoside, demonstrated anti-tumor activities (Xiong et al. 2009; Lee et
al.). In addition, the polyphenolic structure of SsnB also reveals much about its potential
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therapeutic effects. Many plant-derived polyphenols have demonstrated antiinflammatory and anti-angiogenic properties. Quercetin and resveratol, both polyphenols
isolated from red wine, have demonstrated anti-inflammatory and anti-angiogenic
properties. In addition, oleuropein and hydroxytyrosol, both derived from virgin olive
oil, reduce angiogenesis by inhibiting matrix metalloproteinase-9 (MMP-9) and
cyclooxygenase-2 (COX-2) (Scoditti et al. 2012). Emodin, another plant-derived
polyphenol similar to SsnB, has also been shown to inhibit angiogenesis by targeting
endothelial cell proliferation (Kwak et al. 2006). Emodin causes a downregulation of
CCNB1 and CDC2 and a cell cycle arrest at the G2/M phase (Wang, Wu, and Zhen
2004).
In addition to its effects on the cell cycle and cell proliferation, SsnB also affects
other key steps of angiogenesis, including cell migration and chemotaxis. The
microarray data for both HUVECs and HCAECs demonstrates an enrichment of genes
associated with both pathways, including diaphanous homolog 3 (DIAPH3), hyaluronanmediated motility receptor (HMMR), and anillin (ANLN), an actin binding protein.
Furthermore, it is also important to investigate potential upstream pathways that lead to
the alterations in gene expression seen in the microarray data. Previously published data
have shown that SsnB can suppress the NF-κB pathway, and prior studies have
demonstrated a link between NF-κB signaling and expression of cell cycle proteins.
Genes for these regulatory proteins, such as CCNE2, CDC6, CCNB1, and CDC2, contain
binding sites for NF-κB (Hsu, Lee, and Pan; Cude et al. 2007; Liu et al. 2009; Wang et
al.; Meteoglu et al. 2008). SsnB may suppress the NF-κB pathway and cause a
subsequent downregulation of the cell cycle regulatory proteins CCNE2 and CDC6.
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SsnB has also been shown to inhibit the MAPK pathways, including JNK, ERK, and p38
signaling, which all affect gene expression and cell proliferation. We need to explore
these relationships as potential mechanisms of angiogenesis inhibition.
Our current study with HUVECs and HCAECs demonstrates that SsnB inhibits
angiogenic processes in functional assays, including the Matrigel tube assay, Transwell
insert cell migration assay, and microarray analysis. Our next step is to demonstrate the
in vivo / ex vivo efficacy of SsnB, to further evaluate its potential as an anti-angiogenic
agent.
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CHAPTER 3
THE UTILIZATION OF THE CHICK CHORIOALLANTOIC MEMBRANE ASSAY TO EXAMINE THE
EX VIVO ANTI-ANGIOGENIC EFFECTS OF SPARSTOLONIN B.
Abstract
Pathological angiogenesis plays a significant role in many disorders, including
atherosclerosis, diabetic retinopathy, and cancer. Inhibiting angiogenesis may offer a
potential treatment for angiogenesis-dependent disorders. Sparstolonin B (SsnB), a novel
bioactive compound isolated from Sparganium stoloniferum, has demonstrated the ability
to inhibit pro-angiogenic functions in endothelial cells. In functional assays, SsnB
inhibited endothelial cell tube formation (Matrigel method) and cell migration (Transwell
method) in a dose-dependent manner. Microarray experiments with human umbilical
vein endothelial cells (HUVECs) and human coronary artery endothelial cells (HCAECs)
demonstrated differential expression of genes associated with cell proliferation and cell
cycle. SsnB may exert its anti-angiogenic properties by downregulating CCNE2 and
CDC6, halting progression through the G1/S checkpoint. To investigate the effects of
SsnB on ex vivo angiogenesis, a chick chorioallantoic membrane (CAM) assay was
utilized. Chick embryos were exposed to methylcelluose discs containing vehicle control
(DMSO) or 100 micromolar SsnB. Chick embryos receiving SsnB discs showed
significant reduction in capillary length and branching number relative to the vehicle
control group. Overall, SsnB caused a significant reduction in angiogenesis,
demonstrating its ex vivo efficacy.
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Introduction
Angiogenesis refers to capillary formation from existing blood vessels; it is a
complex process that occurs in several stages and involves interactions between cells,
soluble factors, and extracellular matrix molecules. Endothelial cells play a key role in
angiogenesis. First, proteolytic enzymes break down the basement membrane of an
existing blood vessel and endothelial cells invade the surrounding tissues, migrate, and
proliferate. Growth factors and other soluble proteins in the ECM, including Vascular
Endothelial Growth Factor (VEGF), facilitate and regulate this process. After migration
and proliferation, the endothelial cells form a new lumen and start to secrete extracellular
matrix molecules, ultimately forming a new capillary. Supporting cells, such as pericytes
and smooth muscle cells, and extracellular matrix proteins are also extensively involved
in the process (Bussolino, Mantovani, and Persico 1997; Carmeliet 2003; Liekens, De
Clercq, and Neyts 2001).
Angiogenesis plays an important role in many normal physiological functions and
numerous pathological conditions. Physiological processes include embryonic
development, wound healing, and changes in the endometrial wall. Pathological
processes that involve angiogenesis include atherosclerosis, psoriasis, rheumatoid
arthritis, and tumor growth and metastasis. Targeting angiogenesis may provide a
potential therapy for these pathological disorders. Angiogenesis may be inhibited at
multiple steps. Growth factors, including Vascular Endothelial Growth Factor and basic
Fibroblast Growth Factor, are a suitable target. Current approaches to sequester VEGF
include soluble VEGF receptors and neutralizing antibodies against VEGF. Intracellular
signaling molecules, including tyrosine kinases, can be inhibited to prevent receptor37

mediated activation of endothelial cells. There also exist natural angiogenesis inhibitors,
including endostatin, retinoids, and fibronectin fragment, which may be targeted for
angiogenesis inhibition. Angiogenesis inhibitors often target endothelial cells through
the inhibition of cell proliferation, migration, and protease production (Pandya, Dhalla,
and Santani 2006). Current research into angiogenesis inhibition has demonstrated ways
to limit atherosclerosis. By inhibiting intraplaque angiogenesis, necessary factors, such
as inflammatory cells and mediators, are not delivered to the growing plaque, diminishing
plaque growth. Plaque stability may also improve, decreasing the likelihood of plaque
rupture and subsequent thrombosis and stroke or myocardial infarction (Virmani et al.
2005; Moreno et al. 2004; Sridhar and Shepherd 2003).
Sparstolonin B (SsnB) is a novel compound isolated from the plant Sparganium
stoloniferum, a perennial, aquatic plant grown in North and East China. Dried powder
and extracts derived from Sparganium stoloniferum have been used for centuries in
Chinese folk medicine for the treatment of inflammatory diseases, seizures, and blood
stasis. These compounds are also widely used to treat gynecological problems, including
amenorrhea and cancer, such as hysteromyoma. Most significantly, one such extract has
shown the ability to inhibit angiogenesis and estrogen-mediated activities (Sun, Wang,
and Wei 2011). Extracts containing active components are isolated from the root-like
modified stem of the plant, known as the rhizome or tuber. A typical extraction protocol
involves drying the rhizome and grounding it into a powder. The powder is mixed in
boiling distilled water to produce an aqueous solution. Extracts may also be prepared
with organic solvents, including ethanol, choloroform, and ethyl acetate. Extracts contain
a multitude of active components including flavonoids, phenylpropanoid glycosides,
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aromatic acids, and polyphenols (Wu et al. 2012). Sparstolonin B isolation was begun by
soaking the powdered tuber in 85% ethanol overnight and extracting three times with the
same solvent. The solvent was filtered and concentrated under vacuum, producing a
residue, which was then dissolved in water and extracted with petrol, ethyl acetate, and nbutyl alcohol in sequential order. This extract was run through a silica gel column and
eluted with petrol - ethyl acetate mixtures with increasing polarities. The end product
was yellow needles containing SsnB (Liang et al. 2011).
The potential effects that SsnB may have on biological pathways may be revealed
by its chemical structure. The structure of SsnB is very similar to isocoumarin or
xanthone, both compounds know for anti-coagulant, anti-inflammatory, and anti-tumor
properties. Furthermore, the polycyclic / polyphenolic structure is suggestive of the
ability of SsnB to serve as an angiogenesis inhibitor (Liang et al. 2011). Polyphenolic
compounds derived from plants, including olives and grapes, have been shown to have
anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.
Compounds derived from green tea and red wine, particularly quercetin and resveratrol,
have both demonstrated angiogenesis inhibition (Scoditti et al. 2012). Similarly, we have
shown the ability of SsnB to inhibit in vitro angiogenesis. In functional assays with
endothelial cells (HUVECs, HCAECs, and HMVECs), SsnB has demonstrated the ability
to inhibit key steps of angiogenesis, including morphogenesis, cell migration,
chemotaxis, and cell cycle progression. Using microarrays, we have shown that SsnB
altered gene expression in pathways associated with the cell cycle, cytoskeleton, and
cytokinesis. Furthermore, published research has shown that SsnB blocks Toll-like
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receptor 2 and Toll-like receptor 4 mediated inflammation in human and murine
macrophages (Liang et al. 2011).
Preliminary research into angiogenesis inhibitors or stimulators often begins with
simple in vitro assays using endothelial cells, such as the Matrigel tube formation assay
or Transwell insert migration assay. However, these assays only study isolated functions
of endothelial cells. Angiogenesis is a multicelllular event that also incorporates
interactions with extracellular components. In order to fully prove that a compound
inhibits or stimulates angiogenesis, an in vivo or ex vivo assay must be utilized to address
the complex, multicellular nature of angiogenesis. Several commonly used in vivo assays
include the Matrigel plug, corneal angiogenesis, and hamster cheek pouch assays. The
chick chorioallantoic membrane (CAM) assay is also widely used to study ex vivo
angiogenesis. The assay is simple and reproducible, and it reveals more important
information than in vitro assays (Auerbach et al. 2003). The CAM is used for gas and
nutrient exchange in the chick embryo during development. Figure 3.1 illustrates the
organization of a typical CAM. The allantois appears 3 days after incubation as an
evagination from the endodermal hind gut. After spreading into the extraembryonic
coelom, the allantoic vesicle enlarges rapidly. The mesodermal layers of the allantois
and chorion fuse to form the chorioallantoic membrane. This double layer becomes
highly vascularized as blood vessels develop. Within the CAM, single walled immature
blood vessels develop first, eventually forming a capillary plexus around day 8. All
vessels are connected to branches from the two main chorioallantoic arteries and one
chorioallantoic vein. At day 18, the vascular system reaches its final organization.
Located near the porous shell, the highly vascularized CAM allows exchange of oxygen
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and carbon dioxide and serves as an area to store waste products, including urea and uric
acid. The rapidly developing vascular system in the CAM provides an ideal environment
to study how compounds affect angiogenesis (Ribatti 2008).

Figure 3.1 Chick embryo demonstrating chorioallantoic membrane vascularization.
In the CAM assay, test compounds are added to the surface of the CAM, and their
effect on angiogenesis is examined. Delivery systems include synthetic polymer discs,
gelatin sponges, or glass coverslips. One of the most popular methods involves the
creation of discs made from a solution of 1% methylcellulose mixed with the test
compound. Methylcellulose discs allow slow release and minimal adverse biological
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reaction (Swiercz et al. 1999). This assay may be completed with or without the intact
shell (in ovo and ex ovo, respectively). For the in ovo method, eggs are incubated for 7 to
9 days, and a square hole is cut in the shell after removing albumin with a fine needle.
Through this window, the test compounds are added. The window is sealed, and eggs are
placed back in an incubator for 2 or 3 days. The in ovo method maintains a more
physiological environment, but provides a very limited area of the CAM with which to
work. In the shell-less or ex ovo method, day 3-4 incubated eggs are carefully cracked
open, and the egg contents are transferred to plastic petri plates. The plates are incubated
for an additional 2 to 6 days. This is technically a whole-animal assay, even though it
shares much in common with in vitro assays. The ex ovo method provides a large surface
area of the CAM to place test substances and easily document with time lapse
photography. However, a high mortality rate is often associated with the ex ovo method,
sometimes reaching 50% dead after the first three days (Dohle et al. 2009; Ribatti 2008;
Auerbach et al. 2003).
In both assays, the angiogenic response in the CAM may be measured in
numerous ways. For analysis, pictures may be taken at the end of the experiment or over
time to document the progression of blood vessel growth. However, time progression
photos involve excessive handling of the embryos, which increases the embryonic
mortality rate. Images from the area surrounding and underneath the test compound may
be qualitatively scored on a numeric scale, such as 0 to 4, based on vascularization.
Qualitative analysis is quick and reproducible, but it requires initial serial dilution assays
with controls to establish the grading scale. Quantitative methods have proven more
accurate and less prone to human error. Quantitative techniques include the measurement
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of blood vessel number, length, and area. Another quantitative procedure involves
counting the number of converging vessels with superimposed rings on the CAM image.
To address blood vessel branching, the number of bifurcation points may be counted, or
fractal pattern analysis may be utilized. In addition, the total blood vessel volume in the
CAM may be measured by injecting thymidine or a colorimetric / fluorescent dye. Many
of these quantitative techniques involve time consuming manual analysis of images,
which can be overcome with automated analysis by computer software algorithms
(Ribatti 2008; Blacher et al. 2001).
Our preliminary studies with HUVECs, HCAECs, and HMVECs have shown
evidence of the anti-angiogenic effects of SsnB in the Matrigel tube assay and the
Transwell insert cell migration assay. However, we must also demonstrate the in vivo or
ex vivo efficacy of SsnB if we would like to further evaluate SsnB as a potential
pharmaceutical agent. The in vitro assays alone are not sufficient in this regard. We
demonstrated the ex vivo anti-angiogenic effects of SsnB with the chick chorioallantoic
membrane (CAM) assay.
Experimental Procedures
Materials - Sparstolonin B was purified from the plant Sparganium stoloniferum
according to previously published methods (Liang et al. 2011). Fresh fertilized bovans
eggs were obtained from Clemson University and stored at 4°C for no longer than one
week.
Methylcellulose Discs - Methylcellulose discs were created with a solution of
0.5% methylcellulose (diluted in sterile deionized water). A methylcellulose solution of
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100 micromolar SsnB was made by adding 1.1 microliters of stock SsnB (93 mM) to 1
ml 0.5% methylcellulose. A vehicle control solution was created by adding 1 microliter
of dimethyl sulfoxide (DMSO) to 1 ml 0.5% methylcellulose. Discs were created by
placing 20 microliter droplets of SsnB or vehicle control solution onto
polytetrafluoroethylene tape (to minimize adherence during drying) and allowed to dry
under a laminar flow hood.
Chick Chorioallantoic Membrane Assay - The fertilized eggs were placed in a
humidified egg incubator with forced air circulation at 37°C. The eggs were
automatically rotated every three hours. After 4 days of incubation, the eggs were
removed and cracked. Chick embryos with intact yolks were placed in 100 mm petri
plates. Each petri plate was placed in a weigh boat containing 13 ml Moscona’s buffer
and covered with cellophane wrap with two holes for air circulation. The plates were
placed in a water-jacketed incubator (37C, 5% CO2) for 2 days. After 2 days of
incubation, the methylcellulose discs containing either SsnB or vehicle control were
placed on top of the CAM of each embryo in the right upper quadrant in an area near the
allantoic vessels. After 2 additional days of incubation, the CAMs were examined and
photographed with a dissecting stereomicroscope. Images were taken of areas containing
the discs and non-treated regions. Each group contained seven embryos (calculated with
PS 3.0.5 software, effect size of 50%, standard deviation of 30%, statistical power of 0.8,
and α=0.05). The CAM assay was completed two times.
Image Analysis - Images were analyzed with Image-Pro Plus software. Blood
vessel length and branching number were utilized to measure the effect of SsnB on
angiogenesis. The vessel length was measured for areas containing the discs and non44

treated regions. Normalized vessel length was calculated by dividing the length values
of the treated regions by those of the non-treated regions. The same process was repeated
for measuring the branching number.
Statistical Analysis - To determine if a statistically significant difference between
the treatment groups in each experiment existed, a one-way analysis of variance test
(ANOVA) was completed.
Results
SsnB inhibits angiogenesis in the CAM assay - Initial in vitro studies with SsnB
and endothelial cells have demonstrated the ability of SsnB to inhibit important cellular
aspects of angiogenesis, including tube formation, cell migration, cell cycle progression,
and chemotaxis. However, these in vitro results were not conclusive in proving the antiangiogenic properties of SsnB. We utilized a chick chorioallantoic membrane assay to
successfully demonstrate that SsnB inhibits ex vivo angiogenesis. The results from the
CAM assay are depicted in Figure 3.2. Overall, SsnB resulted in a significant decrease in
normalized blood vessel length compared to the vehicle control group (ANOVA, p <
0.05).
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Figure 3.2 SsnB reduces normalized blood vessel length in the CAM assay.
In addition to inhibiting blood vessel length, SsnB also caused a significant
decrease in the normalized branch number. The results are depicted in Figure 3.3.
Compared to the vehicle control, SsnB decreased the number of points where blood
vessels branched into two or more separate vessels. Interestingly, it has been shown that
macrophage production of matrix metalloproteinases is important for blood vessel
branching. SsnB may be inhibiting this process by blocking TLR activation of
macrophages.
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Figure 3.3 SsnB reduces normalized branch number in the CAM assay
Representative images of the CAM from the SsnB and vehicle control groups
after two days of treatment are shown in figure 3.4. The methylcellulose discs released
SsnB or vehicle control and were still present at the end of the experiment, as complete
biodegradation did not occur. The transparency of the methylcellulose discs allowed
easy imaging of the vascular network underneath the discs. Images were taken of regions
of the CAM that received methylcellulose discs as well as regions that did not receive
discs. For each embryo, the blood vessel length and branch number were measured for
both treated and non-treated areas. A normalized value was calculated by dividing the
treated areas by the non-treated areas. This approach allowed us to compensate for
natural variations in vascular density among embryos that normally occur without the
presence of angiogenic inhibitors or stimulators. Overall, the SsnB-treated group showed
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fewer blood vessels, smaller vessel lengths, and fewer branches. The methylcellulose
discs with SsnB not only inhibited angiogenesis in the area underneath the disc, but also
demonstrated inhibition in the immediate area surrounding the discs. Compared to the
SsnB group, the vehicle control group exhibited higher vessel lengths, more vessels, and
more vascular branching. Furthermore, SsnB treatment was associated with a decrease in
blood vessel diameter and size.

Figure 3.4 Representative images from CAM assay.
In addition, SsnB had no effect on the viability or morphology of the embryos
relative to the vehicle control. Both groups experienced similar number of embryo
deaths, which is typically encountered with the CAM assay. The embryos that survived
until the end of the experiment exhibited no obvious differences in size or morphology
between the two groups.
Discussion
We demonstrated that SsnB inhibits endothelial cell functions related to
angiogenesis in several in vitro functional assays. The data suggests the potential of
SsnB as an anti-angiogenic agent by showing inhibition of human endothelial cell tube
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formation, migration, and chemotaxis. We have also found evidence supporting the
cytostatic nature of SsnB by showing that it inhibits endothelial cell progression through
the cell cycle. In this work, we have also demonstrated that SsnB inhibits ex vivo
angiogenesis in the CAM assay.
Angiogenesis is a complex process comprised of numerous steps. The process is
initiated by endothelial activation, often by growth factors, such as VEGF and FGF.
Activated endothelial cells proliferate, secrete proteases, and migrate, eventually forming
capillary tubes with complete lumens. Each of these steps may serve as a potential target
for anti-angiogenic agents. SsnB is capable of inhibiting angiogenesis by targeting
multiple steps in the angiogenesis pathway (Roy et al. 2006). We have previously shown
that SsnB is capable of inhibiting tube formation and cell migration in the Matrigel tube
assay and Transwell insert migration assay, respectively. We have also shown SsnB
arrests endothelial cell division in the G1 phase of the cell cycle with associated
downregulation of the cell cycle regulatory proteins, cdc6 and cyclin E2. This cell cycle
arrest allows SsnB to act as a cytostatic agent, slowing endothelial division. Finally, we
have shown that SsnB inhibits ex vivo angiogenesis in the CAM assay. The evidence to
date suggests that SsnB is an effective inhibitor of angiogenesis, and may prove to be a
suitable therapeutic alternative to treat disorders in which excessive blood vessel growth
contributes to the pathology, including cancer, rheumatoid arthritis, and psoriasis
(Mombeinipour et al. 2013). SsnB may particularly be suited to treat atherosclerosis due
to its combined anti-angiogenic and anti-inflammatory properties. Inhibiting
angiogenesis may prevent intraplaque angiogenesis, thereby limiting plaque growth,
destabilization, and subsequent rupture. At the same time, SsnB may inhibit the chronic
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inflammatory reactions necessary for plaque formation and growth (Moreno et al. 2004;
Virmani et al. 2005).
SsnB is derived from the plant, Sparganium stoloniferum, an aquatic herb that has
been used to treat a multitude of disorders including cancer. Past research with this herb
has demonstrated its use to treat cancer, seizure disorders, and inflammatory diseases
(Wu et al. 2012). Especially relevant to our research, Sun et al demonstrated the antiangiogenic effects of an aqueous extract from Sparganium stoloniferum. In their
research, pregnant mice were administered the aqueous extract, and the offspring from
these mice were examined and compared to controls. The offspring exhibited numerous
morphological abnormalities, related to disrupted angiogenesis and estrogen signaling,
including limb, heart, vertebral, and craniofacial defects. FGF and VEGF levels were
lowered in the offspring, causing decreased angiogenesis. A disruption in FGF signaling
is also known to cause defects in limb bud and cranial formation and heart development.
Anti-estrogen activity was implicated in increased numbers of male offspring relative to
female offspring. The aqueous extract utilized in Sun’s research contained a multitude of
active components (Sun, Wang, and Wei 2011). Our research only focused on one
particular active compound from Sparganium stoloniferum.
Prior research with SsnB has demonstrated its ability to inhibit inflammation.
Specifically, SsnB was shown to inhibit Toll-like Receptor 2 (TLR-2) and Toll-like
Receptor 4 (TLR-4) mediated inflammation, by acting as an antagonist to both receptors.
Inflammatory cytokine production from lipopolysaccharide (LPS)-treated macrophages
and mice was inhibited by SsnB treatment. SsnB inhibits toll-like receptors
intracellularly, somewhere between ligand binding and immediate adaptor recruitment
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(for example, MyD88). SsnB may act directly on TLR2 and TLR4 TIR domains or
TIRAP/mal protein, which is an indispensable adaptor bridging TLR2/TLR4 TIR domain
and MyD88 interaction (Liang et al. 2011). Toll-like receptors are mainly involved in the
innate immune system, where they activate inflammatory pathways to deal with
pathogens. However, toll-like receptors have also been shown to be implicated in cancer
cell proliferation and metastasis. Functional TLRs are expressed on many different
tumor cell types; their activation stimulates cell proliferation and escape from apoptosis.
TLRs may also enhance expression and activation of metalloproteinases and integrins,
resulting in increased cancer cell invasion and metastasis. TLR signaling may also
provide cancer cells with resistance to the host immune system through upregulation of
immunosuppressive molecules and inhibitory cytokines (Huang et al. 2008). Overall,
SsnB blocks the TLR signaling pathway, preventing many of the steps described above,
some of which are also important in angiogenesis. Thus, it is conceivable that SsnB may
block cancer progression by multiple mechanisms in addition to inhibiting angiogenesis.
SsnB crosses the cell membrane and works intracellularly to suppress signaling
pathways. Previously published data has shown that SsnB can suppress the NF-κB
pathway, and prior studies have demonstrated a link between NF-κB signaling and
expression of cell cycle proteins. Genes for these regulatory proteins, such as CCNE2,
CDC6, CCNB1, and CDC2, contain binding sites for NF-κB. SsnB may suppress the
NF-κB pathway and cause a subsequent downregulation of the cell cycle regulatory
proteins CCNE2 and CDC6. SsnB has also been shown to inhibit the MAPK pathways,
including JNK, ERK, and p38 signaling, which all affect gene expression and cell
proliferation. In the future, we need to explore these relationships as potential
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mechanisms of angiogenesis inhibition (Hsu, Lee, and Pan; Cude et al. 2007; Liu et al.
2009; Wang et al.; Meteoglu et al. 2008; Liang et al. 2011).
We hypothesize that the main activity of SsnB involves a cytostatic effect
whereby it limits endothelial cell cycle progression by trapping cells in the G1 phase of
the cell cycle. This is accomplished by downregulating two key regulatory proteins, cdc6
and cyclin E2, that are necessary to progress beyond the G1/S checkpoint. As a result
endothelial cell progression through the cell cycle is slowed down, limiting necessary cell
proliferation required for angiogenesis. Emodin, a structurally similar plant-derived
polyphenol, has also been shown to inhibit angiogenesis by targeting endothelial cell
proliferation (Kwak et al. 2006). Emodin causes a downregulation of CCNB1 and CDC2
and a cell cycle arrest at the G2/M phase (Wang, Wu, and Zhen 2004).
In addition, we also hypothesize that SsnB may inhibit endothelial cell migration
and tube formation, additional steps required for angiogenesis, by modulating
cytoskeletal reorganization. The microarray data for both HUVECs and HCAECs
demonstrates an enrichment of genes associated with cell motility and cytokinesis,
including cytoskeleton associated protein 2-like (CKAP2L), diaphanous homolog 3
(DIAPH3), hyaluronan-mediated motility receptor (HMMR), and anillin (ANLN), an
actin binding protein. All four genes are involved with the cytoskeleton, cytokinesis, and
stress fiber formation (Piekny and Maddox 2010; Yang et al. 2007; Yang et al. 2010). In
the tube formation experiments, SsnB seemed to change cell shape, and this may be
caused by changes in the cytoskeleton. We need to further investigate how SsnB affects
endothelial cell shape, cytoskeleton arrangement, and stress fiber formation, and how
cytoskeletal effects interact to reduce cell migration and tube formation.
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Furthermore, the CAM assay allowed us to examine the effects of SsnB on
additional cell types beyond endothelial cells. Multiple cell types are involved in
angiogenesis, including endothelial cells and supporting cells, such as pericytes, smooth
muscle cells, macrophages, and myofibroblasts. Since our initial in vitro experiments
only involved endothelial cells, we utilized the CAM assay to address the multicellular
nature of angiogenesis. We are particularly interested in how SsnB affects macrophages.
In the CAM assay, SsnB inhibited blood vessel branching. It has been demonstrated that
macrophage production of matrix metalloproteinase-9 (MMP-9) plays an important role
in vascular branching during neovascularization (Johnson et al. 2004). Prior research has
shown that SsnB blocks TLR-2 and TLR-4 mediated inflammation in human and murine
macrophages. Furthermore, TLR signaling activates MMP production in macrophages
(Huang et al. 2008). We hypothesize that SsnB blocks TLR signaling and subsequently
inhibits macrophage MMP-9 production required for blood vessel branching. Additional
experiments could examine this relationship between SsnB, TLR signaling, macrophage
production of MMP-9, and vascular branching.
Overall, SsnB exhibits many diverse effects, including anti-angiogenic, and
cytostatic properties, which may contribute in part to the traditionally reported results of
treatment with Sparganium stoloniferum and its extracts.
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CHAPTER 4
DISCUSSION
Angiogenesis plays an important role in physiological and pathological processes.
Unregulated angiogenesis contributes to many pathological conditions, such as
rheumatoid arthritis, psoriasis, retinopathy, and tumor growth and metastasis.
Angiogenesis also plays a significant role in atherosclerosis. Capillary networks within
atherosclerotic plaques can serve as a source of inflammatory cells and mediators,
promoting plaque formation. Recent research has suggested that inhibiting angiogenesis
may improve plaque stability and decrease plaque formation by limiting this supply of
necessary factors to the growing plaque (Griffioen and Molema 2000).
Complementary and alternative medicine is a growing area of research which may
hold the key to treatment of numerous disorders, including ones associated with
angiogenesis. Researchers have often looked towards herbal medicine, which has been
used in many countries throughout the world for centuries, for sources of biologically
active molecules. Herbal remedies play a large role in Traditional Chinese Medicine,
where plants and plant-derived extracts and compounds are used to treat a multitude of
disorders. Many plants secrete bioactive compounds as a defense mechanism to deal
with pests. These bioactive compounds exhibit an array of effects, including cytotoxic or
cytostatic properties. Many modern day drugs have been isolated and characterized from
these plants, which have played a large role in Traditional Chinese Medicine (Qin and Xu
1998; Zhou and Wu 2006).
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One such herb, Sparganium stoloniferum, has been extensively used in Chinese
herbal medicine to treat a variety of disorders, including seizures, amenorrhea, and
cancer. Sparganium stoloniferum is an aquatic plant which grows in the northern and
eastern regions of China (Wu et al. 2012; Sun, Wang, and Wei 2011). Sparstolonin B, a
bioactive compound isolated from S. stoloniferum, has already been shown to act as a
potent anti-inflammatory agent. In experiments with mouse and human macrophages,
SsnB inhibited Toll-like receptor (TLR) 2 and 4 mediated inflammation, decreasing
cytokine release. SsnB crosses the cell membrane and inhibits the TLRs by blocking
MyD88 recruitment, an important step in TLR signaling. SsnB belongs to the polyphenol
family of compounds; its structure is similar to isocoumarin and xanthone, both strong
anti-inflammatory compounds (Liang et al. 2011).
We have demonstrated the potential of Sparstolonin B as an inhibitor of
angiogenesis. SsnB inhibited angiogenesis-related cell activities in functional assays in
vitro, altered the expression of angiogenesis related genes, and inhibited ex vivo
angiogenesis. The first part of the project showed that SsnB inhibited angiogenic
activities of endothelial cells in functional assays, including the Matrigel tube formation
assay and the Transwell cell migration assay. In the second part of the project, we
utilized microarrays and qRT-PCR to demonstrate that SsnB altered the expression of
genes in HUVECs and HCAECs related to cell cycle progression, cytokinesis, nuclear
division, cytoskeleton, and chemotaxis, all important pathways in angiogenesis. We were
especially interested in the downregulation of the cell cycle proteins CCNE2 and CDC6,
which control progression through the G1/S checkpoint. Using flow cytometry, we
demonstrated that SsnB blocked cell cycle progression at this checkpoint. In the third
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part of the project, we showed that SsnB blocked ex vivo angiogenesis in the chick
chorioallantoic membrane assay. Overall, SsnB may prove to be a successful alternative
therapy for angiogenesis-related disorders, including cancer, rheumatoid arthritis, and
atherosclerosis.
SsnB inhbits angiogenic functions in endothelial cells
In the first part of the project, we demonstrated that SsnB inhibits endothelial cell
activity in several functional assays. SsnB caused a dose-dependent reduction of total
tube length in the Matrigel tube formation assay with HUVECs, HCAECs, and
HMVECs. Increasing the concentration of SsnB from 1 to 100 micromolar increased the
level of inhibition compared to the vehicle control. In all the SsnB treatment groups, the
endothelial cells showed morphological changes, including cell rounding and clumping.
We initially believed that this might be a sign of cell death or apoptosis induced by SsnB.
However, a live/dead assay showed that SsnB had no effect on cell viability. In all SsnB
treatment groups, we observed no cell death; all cells stained positively for viable cells.
We hypothesize that SsnB is affecting pathways related to cell morphology and motility.
Anti-angiogenic agents often inhibit cell motility by targeting the actin cytoskeleton and
microtubule system (Karna et al. 2012). SsnB may be acting in this manner, preventing
the necessary changes in cell shape and movement necessary for tube formation in the
Matrigel assay. This would also explain the changes in morphology and cell clumping
seen in our Matrigel assays.
In addition, SsnB treatment resulted in a dose-dependent inhibition of endothelial
cell migration in the Transwell insert assay. HUVECs and HCAECs experienced a dose-

56

dependent inhibition in migration in response to SsnB concentrations from 0.0001 and
0.1 µM that reached a plateau between 0.1 and 100 µM of SsnB. The cell migration
assay relied upon VEGF-directed chemotaxis. Therefore, SsnB must somehow interfere
with chemotaxis, through mechanisms which could range from inhibition of VEGF
signaling to impaired cell motility or adhesion. Our microarray datasets demonstrated an
enrichment in genes associated with chemotaxis, cytoskeleton, and cell adhesion, which
may provide clues as to how SsnB inhibits cell migration. Perhaps SsnB is causing
endothelial cells to adopt an adhesive state, limiting chemotaxis. Compared to the
Matrigel tube formation assay, the cell migration assay demonstrated a dose-dependent
inhibition at lower concentrations of SsnB (between 0.0001 and 0.1 µM), which reached
a plateau at 0.1 µM. This may indicate that cell migration is more sensitive to SsnB
exposure compared to tube formation.
The inhibition in tube formation and cell migration by SsnB may involve
targeting the cell motility apparatus through alterations in the actin cytoskeleton and
microtubule system. The cytoskeleton is the main driving force for cell movement and
shape change. Actin is the key component of the cytoskeleton, which controls cell
locomotion. Cellular movement involves a coordinated effort of actin polymerization
and depolymerization, as well as focal adhesion assembly and disassembly.
Microtubules interact with the actin cytoskeleton, provide structural support, and play a
key role in establishing cell polarity and centrosome orientation. These processes help
establish a leading edge in the cell that is utilized for directed movement. Intermediate
filaments, including vimentin, are important components of the cytoskeleton, providing
cell shape and participating in interactions between actin filaments and microtubules.
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Stress fibers and focal adhesions are additional structures associated with the
cytoskeleton that play a strong role in cell movement and migration. Stress fibers
represent organized centers of actin filaments, myosin, and intermediate filaments that
generate force for cell movement, migration, and adhesion. Focal adhesions are complex
protein structures through which the cytoskeleton interacts with the extracellular matrix,
establishing attachment points with the ECM as cell movement occurs. Cell movement is
comprised of three distinct phases (protrusion, attachment, and traction) that all
incorporate interactions between microfilaments, microtubules, stress fibers, and focal
adhesions. Cell motility begins with the protrusion of lamellopodia from the leading
edge of the cell, mainly through actin polymerization. As the lamellopodia extend across
the underlying surface, the cell attaches and detaches to ECM components through
specialized receptors, including integrins. During traction, the bulk of the cell is carried
forward toward the leading edge. Overall, any disruptions in the cytoskeleton or
associated structures lead to inhibition of cell mobility (Fenteany and Zhu 2003;
Lamalice, Le Boeuf, and Huot 2007; Mackay 2008).
Some naturally derived compounds target the actin cytoskeleton or microtubules
to inhibit cytoskeleton dependent functions, including cell migration. They may inhibit
actin / microtubule polymerization leading to cytoskeleton destabilization, or promote
actin / microtubule polymerization leading to cytoskeleton stabilization. In both cases,
cell motility becomes limited due to disruption in normal cytoskeleton functioning,
ultimately inhibiting processes, such as angiogenesis, that depend on cell movement.
Cytochalasins, a group of fungally derived molecules, bind the barbed ends of
microfilaments and block polymerization and depolymerization, effectively capping the
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growing end and preventing extension of actin filaments into the leading edge of the cell.
Phalloidin, another fungally derived compound, stabilizes actin filaments, promotes actin
polymerization, and inhibits depolymerization, locking actin filaments in place (Fenteany
and Zhu 2003). Compounds that target microtubules include taxanes and epothilones,
which inhibit tubulin depolymerization and promote microtubule stabilization, and vinca
alkaloids that inhibit polymerization and mitotic spindle formation (Bijman et al. 2006).
In addition, compounds may also target upstream signaling pathways that control
microfilaments and microtubules. Intracellular targets for microfilament and microtubule
disruption include Rho GTPases, a family of signaling molecules that control cell
motility. Tumor-derived VEGF has been shown to activate Rho GTPases, including
Cdc42, Rac1, and RhoA. Once activated, these signaling molecules affect cytoskeletal
organization, including filopodia, lamellipodia, and stress fibers, all impacting cell shape
and motility. Furthermore, cdc42 affects the orientation of the centrosome and cell
polarity, RhoA controls actin-myosin contraction promoting cell movement, and Rac1
promotes actin polymerization in the leading edge and focal adhesion formation.
Inhibition of these signaling molecules leads to disruptions in the cytoskeleton, stress
fiber formation, and focal adhesion. Many of these inhibitory compounds possess
polycyclic structures and functional groups similar to SsnB (Vincent et al. 2001;
Fenteany and Zhu 2003; Karna et al. 2012). Based on the results from the cell migration
and tube formation experiments, as well as the microarray data described below, we
believe that SsnB may act in part by targeting the cytoskeleton or upstream signaling
pathways to impede changes in cell shape and motility that are both necessary for
angiogenesis.
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SsnB alters endothelial gene expression and limits cell cycle progression
We also demonstrated that SsnB altered the expression of genes implicated in
angiogenesis. Microarray data from human umbilical vein endothelial cells and human
coronary artery endothelial cells showed altered expression in genes associated with a
variety of biological processes, including cell division, cell cycle progression,
chemotaxis, and cytoskeleton, which may provide insight into the results seen in the tube
formation and cell migration experiments. The majority of the enriched genes are also
associated with mitosis. Many genes that are usually upregulated during progression
through the cell cycle to mitosis were downregulated in our microarray data, including
genes such as anillin (ANLN), cyclin E2 (CCNE2), cell division cycle 6 (CDC6), cyclin
B1 (CCNB1), cyclin dependent kinase 1 (CDC2), and aurora kinases A and B (AURKA,
AURKB) (Dephoure et al. 2008). Clearly, SsnB has shown a strong effect on mitosis and
the events preceding mitosis. Downregulation of these genes may hinder the necessary
cell division and proliferation that is required for angiogenesis. Based on our cell cycle
experiments, we believe that SsnB is causing blockage at two checkpoints in the cell
cycle, the G1/S and G2/M checkpoints, with the former checkpoint dominating. Overall,
the microarray data supported the results of our functional assays and provided insight
into the mechanism of inhibitory action through pathways including cell cycle
progression, cytoskeleton alterations, and chemotaxis.
The genes from the microarray data that initially captured our attention were those
involved in the cell cycle. Table 2.1 demonstrates that CCNE2, CDC6, CCNB1, and
CDC2 were all downregulated by SsnB. Cyclins are regulatory proteins that bind and
activate cell dependent kinases, most importantly cyclin dependent kinase 2 (CDK2),
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which phosphorylate additional proteins, initiating a cascade of cellular events that
prepare the cell for mitosis and division. Cyclin levels rise and fall depending on the
phase of the cell cycle. Normally, CCNE2 and CCNB1 rise in the G1/S and G2/M
phases, respectively. CCNE2 binds and activates CDK2, which phosphorylates
retinoblastoma protein, allowing it to dissociate from the E2F transcription factor. E2F is
then free to activate gene transcription and promote progression through the G1/S
checkpoint. CDC6 plays an essential role in chromosome duplication during the S phase.
CCNB1 binds and activates CDC2 during progression through the G2/M checkpoint,
preparing the cell for mitosis (Wu et al. 2009; Borlado and Mendez 2008). The
downregulation of CCNE2 and CDC6 directly supports the G1/S blockage observed in
our cell cycle experiments with synchronized endothelial cells. We believe that SsnB is
downregulating CCNE2 and CDC6, slowing progression through the G1/S checkpoint.
The microarray data also showed a downregulation of CCNB1 and CDC2, which should
trap cells at the G2/M checkpoint and prevent endothelial cells from entering the final
stages of cell division. This effect was less readily seen due to blockage at the G1/S
checkpoint. In non-synchronized (no serum starvation) HUVECs, G2/M blockage was
observed (see Appendix, Figure A.5) but at much lower levels compared to the G1/S
blockage.
In addition to the cell cycle regulatory genes, there were additional genes
associated with mitosis and the cytoskeleton that stood out in our microarray data. The
microarray data showed an enrichment in genes encoding proteins associated with the
spindle, nuclear envelope, chromosome condensation and segregation, and cytokinesis,
all important aspects of mitosis and cell division. SsnB caused a downregulation in the
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expression of anillin (ANLN), an actin binding protein that plays an important role in
cytokinesis, the final stage of cell division. This could inhibit contractile ring formation,
preventing the cytoskeletal changes necessary for cytokinesis (Piekny and Maddox
2010). Decreased expression of anillin might explain the nuclei clumping or double
nuclei that we observed in additional experiments (see Appendix Figure A.6) with
nuclear staining (Hoechst). Our microarray data also contained many examples of
differentially downregulated cytoskeleton- related genes, including transforming acidic
coiled-coil containing protein 3 (TACC3), hyaluronan-mediated motility receptor
(HMMR), and diaphanous homolog 3 (DIAPH3). Downregulation of the protein
products of these genes may have a negative influence on cytoskeleton functioning,
which is essential for not only mitosis and cytokinesis, but for cell motility as well.
DIAPH3 is an essential element in filopodia and lamellopodia formation, both important
processes for cell motility. Downregulation of DIAPH3 may inhibit lamellopodia /
filopodia protrusion and subsequent cell spreading (Yang et al. 2007). This may explain
the cell rounding that we noticed in the tube formation experiments. TACC3 mainly
controls microtubules and is intricately involved with the centrosome and mitotic spindle
apparatus during mitosis. The spindle apparatus is required for separation of sister
chromatids and subsequent nuclear division. Any disruption of this process could
negatively affect cell proliferation. Furthermore, aurora kinases (AURKA and AURKB),
which were also downregulated in our data, help regulate TACC3-mediated formation of
the mitotic spindle apparatus (Piekorz et al. 2002; Kinoshita et al. 2005). Hyaluronanmediated motility receptor (HMMR or RHAMM) is a protein that regulates microtubule
function during mitosis and the turnover of focal adhesions. RHAMM has been shown to
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be important for endothelial cell migration during angiogenesis. Antibodies directed
against RHAMM effectively inhibited angiogenesis associated with cancer (Yang et al.
2010). RHAMM was also downregulated in our microarray data, suggesting its
involvement in the inhibition of endothelial cell migration and angiogenesis seen in our
experiments.
Kinesin family member 18A (KIF18A) is another gene that was downregulated in
our microarray data. Its functions encompass a variety of pathways, including the
cytoskeleton, cell cycle progression, and cell division, which are all the main mechanistic
processes that we believe SsnB targets to inhibit angiogenesis. KIF18A is a molecular
motor that produces force and movement along microtubules to aid in cytoskeleton rearrangement, especially chromosome movement. KIF18A has also been shown to
interact with caveolin-1 (CAV1) (Luboshits and Benayahu 2005, 2007). Caveolin-1 is
involved in cellular pathways associated with cell morphology and stress fiber formation.
Silencing of caveolin-1 has been shown to inhibit angiogenesis through multiple
mechanisms including alterations in cell morphology (increased cell size and stress fiber
formation) and inhibition in cell migration and progression through the G1/S checkpoint.
These findings connect especially well with our results since we demonstrated a similar
behavior in endothelial cells in response to SsnB treatment. We hypothesize that SsnB
may inhibit caveolin-1-mediated activities through downregulation of KIF18A.
Caveolin-1 also signals through the AKT pathway; SsnB may somehow interfere with
this signaling pathway (Madaro et al. 2013). Prior research has shown that SsnB inhibits
NF-κB, ERK, JNK, and p38 pathways in macrophages. Inhibition of the AKT pathway
may be another mechanism to inhibit caveolin-1-mediated signaling. Further research is
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necessary to test this hypothesis. Overall, the combined effects of inhibiting cell cycle
progression, cytokinesis, mitosis, and cytoskeletal function help explain the cytostatic
and anti-angiogenic properties of SsnB.
SsnB inhibits ex vivo angiogenesis
In the final portion of the research project, we utilized the chick chorioallantoic
membrane assay to examine the effects of SsnB on ex vivo angiogenesis.
Methylcellulose discs containing either 100 µM SsnB or vehicle control (0.1% DMSO)
were added to the CAM of chicken eggs. After incubation for two days, the blood vessel
length and branching pattern were examined. SsnB caused a significant reduction in total
blood vessel length compared to the vehicle control group, successfully demonstrating
the ability of SsnB to inhibit ex vivo angiogenesis. We also demonstrated that SsnB
reduced the number of branch points in developing blood vessels.
The CAM assay incorporates multiple cell types, unlike in vitro functional assays.
In vitro assays, including the Matrigel tube formation assay, only examine the effects of a
test compound on one isolated cell type, namely endothelial cells. Oftentimes, a
compound that exhibits anti-angiogenic properties with in vitro functional assays may not
inhibit in vivo or ex vivo angiogenesis. Furthermore, compounds such as SsnB may
inhibit angiogenesis by targeting additional cell types, and this type of interaction can be
revealed by in vivo / ex vivo assays. Angiogenesis is a multicellular process involving
multiple cell types including endothelial cells and supporting cells, such as pericytes,
smooth muscle cells, myofibroblasts, and macrophages. For example, pericytes and
myofibroblasts help produce collagen fibers to create a framework for vessel formation
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during splitting or intussusceptive angiogenesis, and macrophages produce matrix
metalloproteinases that degrade the basement membrane, providing a path for cell
migration. Normal angiogenesis also involves cell interactions with the extracellular
matrix, which are not properly addressed by in vitro assays. Moreover, cultured
endothelial cells have been preselected by passaging to adopt a proliferative phenotype,
which is uncharacteristic of in vivo angiogenesis. The CAM assay includes multiple cell
types and extracellular matrix interactions to address all of these issues associated with in
vitro assays (Ribatti 2008; Cimpean, Ribatti, and Raica 2008). Using the CAM assay, we
demonstrated that SsnB effectively inhibited angiogenesis, by decreasing total blood
vessel length and by reducing branch number. This data demonstrates that SsnB is
capable of inhibiting true, physiological angiogenesis.
Interestingly, SsnB caused a significant reduction in the number of branches in
the developing CAM blood vessels. Blood vessel branch points have been shown to
colocalize with macrophages that secrete matrix metalloproteinases (MMP) which are
necessary for establishing these branch points. MMPs, especially MMP-9, help degrade
the extracellular matrix, providing access routes for endothelial cells to migrate through
the ECM to create new branches from the original blood vessels as angiogenesis
progresses (Johnson et al. 2004). The observed decrease in CAM vessel branching may
reflect an inhibitory action on macrophages by SsnB. Previous research has shown that
SsnB is capable of inhibiting macrophage-mediated inflammation by blocking toll-like
receptor signaling. In addition to its effects on endothelial cells, SsnB may also be
inhibiting macrophage production of MMPs or other proteolytic enzymes, thereby
reducing the density of branching usually seen in angiogenesis in the CAM assay.
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Limitations and Future Work
Although our research has yielded promising results in demonstrating the antiangiogenic potential of SsnB, our results are still constrained by limitations associated
with our experimental models. Initial experiments with SsnB only utilized in vitro assays
to investigate endothelial cells, leaving out supporting cells involved in angiogenesis,
including macrophages, pericytes, and smooth muscle cells. Our in vitro assays also only
investigated three functional aspects of angiogenesis: chemotaxis, tube formation, and
cell cycle progression. Since our microarray data contained such a large number of
differentially regulated genes associated with the cytoskeleton, it would be beneficial to
investigate how SsnB alters the cytoskeleton and how this impacts chemoattractant
driven angiogenesis. We could begin by studying how SsnB alters stress fiber formation
and cell shape through phalloidin staining. This would be helpful in examining the cell
shape changes that were seen in the tube formation experiment. We may also study how
SsnB affects focal adhesion formation with staining for integrins or associated proteins,
such as vinculin (Wickstrom, Alitalo, and Keski-Oja 2004). This would begin to address
the question of whether SsnB is impeding cell migration by causing the endothelial cells
to adopt an adhesive phenotype. Both of the preceding experiments may be utilized
concurrently with a scratch wound healing assay to further investigate the effects on
chemotaxis. In addition, assays with multiple cell types, including supporting smooth
muscle cells or pericytes, may be utilized to examine the impact of SsnB on additional
cell types (Suboj et al. 2012). We may also examine how SsnB affects macrophages in
relation to angiogenesis, including metalloproteinase production. This would expand
upon the results that we saw in the CAM assay in regards to branching inhibition.
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We utilized the CAM assay as an ex vivo assay to investigate the effects of SsnB
in a multicellular environment, incorporating interactions with the ECM. However, the
CAM assay also has associated limitations. The CAM assay is not a mammalian assay;
differences exist between chicken cells and mammalian cells. Since chick embryos do
not have a mature immune system until the late stages of incubation, specific interactions
between SsnB and lymphoid cells, such as T and B lymphocytes, cannot be examined.
Furthermore, nonspecific inflammatory reactions to the methylcellulose discs may occur
as activated macrophages release inflammatory cytokines in response to added
compounds. In addition, the CAM is undergoing constant morphological changes,
including contraction, that may alter the vascular density independent of the tested
compound (Ribatti 2008). The ex ovo version of the CAM assay employed in this project
also exhibited a high mortality rate in embryo survival. The Matrigel plug assay may be
used to overcome these problems and to provide additional support for our findings from
the CAM assay. The Matrigel plug assay is widely used to study in vivo angiogenesis.
The assay is simple, reproducible, and reveals more important information than in vitro
assays, such as the Matrigel tube formation assay. In this assay, Matrigel is injected
subcutaneously in mice. Over time, endothelial cells from each host mouse invade the
Matrigel plugs, producing capillary networks. Drug delivery pumps may be
subcutaneously implanted in the mice during this period to study how test compounds
affect angiogenesis. After enough time has progressed for capillary formation to occur
within the Matrigel, the mice are injected intravenously with Dextran-FITC to allow
visualization and quantification of vessel formation. After removing the plugs, the gross
vessel distribution is noted with a fluorescent dissecting scope, and fluorescent images
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are collected and analyzed (Staton, Reed, and Brown 2009). SsnB is expected to
decrease the number of capillaries that grow into the Matrigel plugs as it has shown the
ability to inhibit angiogenesis for in vitro models and the CAM model. Furthermore, this
assay could provide additional insight into the effects of SsnB on capillary structure and
cell composition. This will provide a more complete picture of how SsnB affects
multiple mammalian cell types, including immune cells.
The Matrigel plug assay only stimulates the growth of capillaries. The hindlimb
ischemia model may be used as an in vivo assay for angiogenesis and arteriogenesis. In
this model, the femoral artery in the hindlimb of the mouse is ligated to provide an area
of ischemia that will stimulate blood vessel formation and remodeling. Decreased
bloodflow in the hindlimb is monitored with Doppler ultrasound. This model stimulates
growth of both capillaries and larger caliber vessels, compared to the Matrigel plug assay
which only stimulates angiogenesis (van Royen et al. 2001). In our CAM assay, we only
studied the effects of 100 µM SsnB on angiogenesis due to the limited number of
embryos that remained viable over the course of the experiment. It would be more ideal
to study the effects of several concentrations of SsnB for a dose-response study. This
may be accomplished with the Matrigel or hindlimb ischemia assays. For the CAM
assay, we based our concentration (100 µM) on results from the in vitro experiments. We
may need to carry out a series of preliminary experiments to test the feasibility of
different delivery methods (osmotic mini pumps or intraperitoneal injections) for SsnB.
These experiments may provide us with more insight into the effective dose ranges of
SsnB for different in vivo models.
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Before beginning additional in vivo experiments, it would be especially helpful to
determine the pharmacokinetics of SsnB. We need to know more about how SsnB is
absorbed through various routes of administration, and which route works best. Using a
murine model, we should investigate how SsnB becomes distributed within the body over
time. This would show us in which tissues SsnB becomes enriched, providing clues into
the bioavailability of SsnB. Furthermore, it would also be interesting to investigate how
the body eliminates SsnB through metabolism and excretion. This could demonstrate
potential toxic byproducts from metabolic degradation of SsnB. To begin the
pharmacokinetic studies, we need to have a method to detect SsnB in plasma and urine
samples. SsnB could be conjugated with markers for detection in these assays, or
antibodies directed against structural motifs of SsnB could be created for ELISAs or
western blots. Overall, SsnB has proven effective in inhibiting angiogenesis in our
experiments, but its efficacy could be improved. SsnB may serve as a starting point for
derivatized compounds. Functional groups may be added or modified to improve the
solubility, bioavailability, and activity of SsnB. These derivatized compounds may also
possess additional therapeutic properties (Liang et al. 1995).
In addition, we could learn more about the mechanism of action for SsnB by
investigating potential binding sites. An understanding of the initial steps of SsnB
binding to endothelial cells will reveal additional details about downstream pathways,
confirming our prior microarray data. The Aryl Hydrocarbon Receptor (AHR) seems a
likely candidate due to the polycyclic structure of SsnB and the connection between the
AHR pathway and inhibition of HIF-1α -driven angiogenesis. The upregulation of AHRassociated genes, NQO1, ALDH3A1, CYP1A1, and CYP1B1, in our preliminary
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microarray data also provides supporting evidence for the Aryl Hydrocarbon Receptor as
a binding site for SsnB. The aryl hydrocarbon receptor binds polycyclic and halogenated
aromatic hydrocarbons. After AHR binding, the AHR ligand complex and the AHR
nuclear translocator (ARNT), also known as hypoxia-inducible factor-1β (HIF-1β), form
a heterodimeric transcription factor. This complex binds to xenobiotic response elements
in the promoter region of target genes. Hypoxia-inducible factor-1α (HIF-1α) is another
basic helix-loop-helix transcription factor that dimerizes with ARNT and mediates VEGF
gene activation during hypoxic conditions. Recent research has suggested a link between
AHR-ARNT signaling and the regulation of angiogenesis. The AHR and HIF-1 α both
compete for the ARNT; therefore, increased activation of AHR can decrease hypoxiadriven angiogenesis. SsnB possesses a polycyclic structure, making it a potential ligand
for the AHR, which may operate through AHR-ARNT signaling to inhibit angiogenesis
(Dong, Ma, and Whitlock 1996; Forsythe et al. 1996; Ichihara et al. 2007; Reyes, ReiszPorszasz, and Hankinson 1992; Schmidt and Bradfield 1996; Wiesener et al. 1998).
Conclusion
In conclusion, Sparstolonin B has shown promise as an effective inhibitor of
angiogenesis. We demonstrated that SsnB inhibited angiogenic functions in several
functional assays, including tube formation and cell migration. Microarray analysis
showed that SsnB caused differential regulation of genes associated with the cell cycle,
cell division, and cytoskeleton. We also showed that SsnB hampered progression
through the cell cycle at the G1/S checkpoint, possibly by downregulation of CCNE2 and
CDC6. SsnB successfully inhibited angiogenesis in the CAM assay, decreasing vessel
length and branching. Future work with SsnB will reveal more about its mechanism of
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action, including cytoskeletal changes and possible binding sites. Overall, SsnB has
proven to be a powerful bioactive compound with a multitude of useful therapeutic
effects, including anti-angiogenesis and anti-inflammation.
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APPENDIX A –SUPPLEMENTARY DATA
Table A.1 Gene function enrichment analysis for HUVECs in response to SsnB
treatment
***Gene Ontology***
C1
C2
C3
118
759
1470
114
759
1386
203
759
3326
123
759
772
15
759
75
13
759
48
64
759
258
107
759
653
49
759
199
54
759
588
576
759
10922
16
759
130
38
759
286
44
759
337
13
759
43
16
759
48
46
759
543
66
759
897
47
759
439
17
759
119
57
759
711
25
759
244
29
759
189
16
759
96
15
759
67
14
759
63
107
759
1541
66
759
897
57
759
214
50
759
168
25
759
202
16
759
113
37
759
290

C4
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432

P-value
0
0
0.000397
0
0.000007
0.000001
0
0
0
0.000013
0.000936
0.000926
0
0
0
0
0.000335
0.000881
0.000001
0.000121
0.000271
0.000614
0
0.000033
0.000002
0.000005
0.000199
0.000881
0
0
0.000037
0.000209
0

Term Name
adenyl nucleotide binding
ATP binding
cell communication
cell cycle
cell cycle arrest
cell cycle checkpoint
cell cycle phase
cell cycle process
cell division
cell proliferation
cellular process
chemotaxis
chromosomal part
chromosome
chromosome segregation
chromosome, pericentric region
cytoskeletal part
cytoskeleton
cytoskeleton organization and biogenesis
cytoskeleton-dependent intracellular transport
DNA metabolic process
DNA repair
DNA replication
DNA-dependent DNA replication
interphase
interphase of mitotic cell cycle
intracellular non-membrane-bound organelle
kinase activity
M phase
M phase of mitotic cell cycle
microtubule
microtubule associated complex
microtubule cytoskeleton
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15

759

63

15432

0.000001

14
17
31
48
58
19
75
71
24
107
140
14
319
134
8
74
217
9
14
74
31
31
47
130
80
14
16
76

759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759

83
105
186
166
226
156
873
806
185
1541
2090
91
5058
1797
37
493
3609
41
46
490
282
304
492
1996
842
43
130
1037

15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432

0.000089
0.000027
0
0
0
0.000367
0.000003
0.000002
0.000025
0.000199
0.000093
0.000225
0
0.000001
0.000589
0
0.000529
0.000245
0
0
0.000042
0.000157
0.000018
0.000545
0
0
0.000926
0.000404

C4
12147
12147
12147

P-value
0.000781
0.000098
0.000001

Term Name
AIG1 family // 9.1E-85
Cyclin, C-terminal // 4.0E-41
Kinesin, motor region // 4.1E-121

C4
2918
2918
2918
2918

P-value
0
0
0.000004
0.000429

Term Name
Cell_cycle_KEGG // GenMAPP
DNA_replication_Reactome // GenMAPP
G1_to_S_cell_cycle_Reactome // GenMAPP
Smooth_muscle_contraction // GenMAPP

***Protein Domain***
C1
C2
C3
4
542
9
6
542
16
12
542
41
***Pathway***
C1
C2
C3
31
180
112
21
180
69
19
180
90
25
180
195

microtubule cytoskeleton organization and
biogenesis
microtubule motor activity
microtubule-based movement
microtubule-based process
mitosis
mitotic cell cycle
motor activity
negative regulation of biological process
negative regulation of cellular process
negative regulation of progression through cell cycle
non-membrane-bound organelle
nucleotide binding
phosphoinositide-mediated signaling
protein binding
purine nucleotide binding
Ras GTPase activator activity
regulation of cell cycle
regulation of cellular process
regulation of cyclin-dependent protein kinase activity
regulation of mitosis
regulation of progression through cell cycle
response to DNA damage stimulus
response to endogenous stimulus
response to external stimulus
response to stimulus
response to stress
spindle
taxis
transferase activity, transferring phosphoruscontaining groups

C1: number of genes in a cluster or list that have this annotation term
C2: number of annotated genes in this cluster or list
C3: number of all genes on array that have this annotation term
C4: number of all annotated genes on array
P-value: binomial approximated p-value for hypergeometric distribution

80

Table A.2 Gene function enrichment analysis for HCAECs in response to SsnB
treatment
***Gene Ontology***
C1
C2
C3
56
214
1470
56
214
1386
15
214
360
13
214
311
87
214
4602
93
214
5029
85
214
772
13
214
48
51
214
258
71
214
653
43
214
199
27
214
588
51
214
2215
179
214
10922
32
214
286
35
214
337
19
214
377
15
214
363

C4
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432

P-value
0
0
0.000177
0.000463
0.000477
0.000574
0
0
0
0
0
0
0.000155
0.000009
0
0
0.000002
0.000194

15
18
6
30
31
28
13
4
45
21
30
9
18
4
21
21

214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214

43
48
34
543
897
439
119
30
711
244
189
42
96
26
618
615

15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432

0
0
0.00001
0
0.000003
0
0
0.000877
0
0
0
0
0
0.000517
0.000162
0.000152

12
12
140
108
60
122

214
214
214
214
214
214

67
63
7906
5631
1541
6494

15432
15432
15432
15432
15432
15432

0
0
0.000019
0.000021
0
0.000008

Term Name
adenyl nucleotide binding
ATP binding
ATPase activity
ATPase activity, coupled
biopolymer metabolic process
catalytic activity
cell cycle
cell cycle checkpoint
cell cycle phase
cell cycle process
cell division
cell proliferation
cellular component organization and biogenesis
cellular process
chromosomal part
chromosome
chromosome organization and biogenesis
chromosome organization and biogenesis (sensu
Eukaryota)
chromosome segregation
chromosome, pericentric region
condensed chromosome
cytoskeletal part
cytoskeleton
cytoskeleton organization and biogenesis
cytoskeleton-dependent intracellular transport
DNA damage response, signal transduction
DNA metabolic process
DNA repair
DNA replication
DNA-dependent ATPase activity
DNA-dependent DNA replication
double-stranded DNA binding
hydrolase activity, acting on acid anhydrides
hydrolase activity, acting on acid anhydrides, in
phosphorus-containing anhydrides
interphase
interphase of mitotic cell cycle
intracellular
intracellular membrane-bound organelle
intracellular non-membrane-bound organelle
intracellular organelle
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62
131
47
45
108
17
13
28
12

214
214
214
214
214
214
214
214
214

2068
7364
214
168
5633
202
113
290
63

15432
15432
15432
15432
15432
15432
15432
15432
15432

0
0.00005
0
0
0.000021
0
0
0
0

13
6
13
25
44
50
13
60
21
56
101
122
44
62
13
33
15
56
21
43
73
7
5
13
43
24
24
30
13
13
28

214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214
214

83
64
105
186
166
226
156
1541
583
2090
3964
6495
1019
2068
91
1302
421
1797
612
493
3609
41
43
46
490
282
304
842
219
43
1037

15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432
15432

0
0.000303
0
0
0
0
0
0
0.000073
0.000001
0
0.000008
0
0
0
0.000564
0.000888
0
0.000142
0
0.000246
0.000002
0.00037
0
0
0
0
0.000002
0.000015
0
0.00059

8
214
143
***Protein Domain***
C1
C2
C3
5
130
47
4
130
29

15432

0.000965

intracellular organelle part
intracellular part
M phase
M phase of mitotic cell cycle
membrane-bound organelle
microtubule
microtubule associated complex
microtubule cytoskeleton
microtubule cytoskeleton organization and
biogenesis
microtubule motor activity
microtubule organizing center
microtubule-based movement
microtubule-based process
mitosis
mitotic cell cycle
motor activity
non-membrane-bound organelle
nucleoside-triphosphatase activity
nucleotide binding
nucleus
organelle
organelle organization and biogenesis
organelle part
phosphoinositide-mediated signaling
post-translational protein modification
protein serine/threonine kinase activity
purine nucleotide binding
pyrophosphatase activity
regulation of cell cycle
regulation of cellular process
regulation of cyclin-dependent protein kinase activity
regulation of DNA metabolic process
regulation of mitosis
regulation of progression through cell cycle
response to DNA damage stimulus
response to endogenous stimulus
response to stress
second-messenger-mediated signaling
spindle
transferase activity, transferring phosphoruscontaining groups
ubiquitin-protein ligase activity

C4
12147
12147

P-value
0.000166
0.00029

Term Name
AAA ATPase, central region // 2.2E-18
BRCT // 9.8E-9
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4
130
4
130
12
130
2
130
2
130
6
130
2
130
***Pathway***
C1
C2
27
60
22
60
16
60

16
31
41
4
3
10
4

12147
12147
12147
12147
12147
12147
12147

0.00003
0.000373
0
0.000884
0.000501
0
0.000884

Cyclin, C-terminal // 4.0E-41
Cyclin, N-terminal domain // 3.6E-14
Kinesin, motor region // 4.1E-121
Lysophospholipase, catalytic domain // 2.4E-63
M-phase inducer phosphatase // 1.7E-30
MCM // 2.1E-66
SMC protein, N-terminal // 3.7E-50

C3
112
69
90

C4
2918
2918
2918

P-value
0
0
0

Term Name
Cell_cycle_KEGG // GenMAPP
DNA_replication_Reactome // GenMAPP
G1_to_S_cell_cycle_Reactome // GenMAPP

C1: number of genes in a cluster or list that have this annotation term
C2: number of annotated genes in this cluster or list
C3: number of all genes on array that have this annotation term
C4: number of all annotated genes on array
P-value: binomial approximated p-value for hypergeometric distribution
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8-Isoprostane in Carotid Artery Sections
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Figure A.1 8-Isoprostane Staining in Sections of Carotid Arteries
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21 day

Figure A.2 SsnB inhibits Matrigel tube formation in HMVECs
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Figure A.3 Heatmap of differentially regulated genes in HUVECs and HCAECs
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Figure A.4 Heatmap of differentially regulated genes in HUVECs and HCAECs
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Figure A.5 SsnB causes G2/M blockage in non-synchronized HUVECs

Figure A.6 Representative images demonstrating double nuclei (indicated by arrows)
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